U.S. patent application number 15/975711 was filed with the patent office on 2019-01-17 for methods for modulating cyclic nucleotide-mediated signaling in cardiac myocytes and compositions.
This patent application is currently assigned to The United States of America as represented by the Department of Veterans Affairs. The applicant listed for this patent is Department of Veterans Affairs. Invention is credited to Matthew Movsesian, Manuela Zaccolo.
Application Number | 20190017035 15/975711 |
Document ID | / |
Family ID | 55525185 |
Filed Date | 2019-01-17 |
View All Diagrams
United States Patent
Application |
20190017035 |
Kind Code |
A1 |
Movsesian; Matthew ; et
al. |
January 17, 2019 |
METHODS FOR MODULATING CYCLIC NUCLEOTIDE-MEDIATED SIGNALING IN
CARDIAC MYOCYTES AND COMPOSITIONS
Abstract
The invention provides a polypeptide possessing
anti-hypertrophic activity in a cardiac myocyte, wherein the
polypeptide is a mutant variant derived from wild-type PDE3A1
protein and wherein the wild-type PDE3A1 protein has the amino acid
sequence given in SEQ ID NO:1 at amino acid position 146 to
1141.
Inventors: |
Movsesian; Matthew; (Salt
Lake City, UT) ; Zaccolo; Manuela; (Oxford,
GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Department of Veterans Affairs |
Washington |
DC |
US |
|
|
Assignee: |
The United States of America as
represented by the Department of Veterans Affairs
|
Family ID: |
55525185 |
Appl. No.: |
15/975711 |
Filed: |
May 9, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14800657 |
Jul 15, 2015 |
9994830 |
|
|
15975711 |
|
|
|
|
62024994 |
Jul 15, 2014 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12Y 301/04017 20130101;
G01N 2500/04 20130101; G01N 2333/916 20130101; G01N 2500/20
20130101; A61K 38/00 20130101; C12N 9/16 20130101; C12Q 1/44
20130101 |
International
Class: |
C12N 9/16 20060101
C12N009/16; C12Q 1/44 20060101 C12Q001/44 |
Goverment Interests
2 GRANT INFORMATION
[0002] This invention was made with government support under
AI066590, HG003706, and CA114993 awarded by the National Institutes
of Health. The United States Government has certain rights in the
invention.
Claims
1.-55. (canceled)
56. A method for preventing, inhibiting or reversing myocardial
hypertrophy comprising administering a vector having a nucleic acid
molecule encoding an isolated or purified polypeptide possessing
anti-hypertrophic activity in a cardiac myocyte, wherein the
polypeptide is a mutant derived from wild-type PDE3A1 protein and
wherein the wild-type PDE3A1 protein has the amino-acid sequence
given in SEQ ID NO:1 at amino acid position 146 to 1141 in a
cardiac myocyte, said vector being genetically modified by
insertion of at least one therapeutic gene into said vector to
produce functional molecules in a sufficient amount to prevent,
inhibit or reverse myocardial hypertrophy in the cell.
57.-103. (canceled)
104. The method of claim 56, wherein the mutant derived from
wild-type PDE3A1 protein is a catalytically compromised mutant of
PDE3A1 protein.
105. The method of claim 104, wherein the catalytically compromised
mutant of PDE3A1 protein is a catalytically inactive mutant of
PDE3A1 protein or a catalytically reduced mutant of PDE3A1
protein.
106. The method of claim 104 or 105, wherein the catalytically
compromised, reduced or inactive mutant of PDE3A1 protein is a
result of a mutation affecting tyrosine-751 (Y751), histidine-836
(H836), histidine-840 (H840), glutamic acid-866 (E866), aspartic
acid-950 (D950), or phenylalanine-1004 (F1004).
107. The method of claim 105, wherein the catalytically inactive
mutant of PDE3A1 protein has a mutation at phenylalanine-1004
(F1004).
108. The method of claim 106 or 107, wherein the mutation is an
amino acid change to an alanine.
109. The method of claim 106 or 107, wherein the mutation is an
amino acid change to any amino acid other than an alanine.
110. The method of claim 109, wherein the amino acid change to any
amino acid other than an alanine is selected from a group of amino
acids consisting of glycine, serine, threonine, cysteine, valine,
leucine, isoleucine, methionine, proline, tyrosine, tryptophan,
phenylalanine, aspartic acid, glutamic acid, asparagine, glutamine,
histidine, lysine or arginine, and wherein not selected from the
group is amino acid present in the wild-type PDE3A1 at a position
to be mutated.
111. The method of claim 56, wherein the mutant derived from
wild-type PDE3A1 protein is a deletion mutant of PDE3A1
protein.
112. The method of claim 111, wherein the deletion mutant of PDE3A1
protein lacks an intact C-terminal catalytic region.
113. The polypeptide of claim 111, wherein the deletion mutant of
PDE3A1 protein comprises an amino-terminal sequence without the
C-terminal catalytic region.
114. The polypeptide of claim 112 or 113, wherein the C-terminal
catalytic region is given in SEQ ID NO:1 at amino acid position 669
to 1108.
115. The polypeptide of claim 113, wherein the amino-terminal
sequence comprises ten or more amino acids having a sequence
identical or homologous to a sequence at amino acid position 146 to
668 in SEQ ID NO:1.
116. The polypeptide of claim 113, wherein the amino-terminal
sequence comprises ten or more amino acids having a sequence
identical or homologous to a sequence in the N-terminal amino-acid
sequence present in PDE3A1 but not in PDE3A3, corresponding to
amino acid position 146 to 483 in SEQ ID NO:1.
117. The polypeptide of claim 113, wherein the amino-terminal
sequence comprises ten or more amino acids having a sequence
identical or homologous to a sequence in the N-terminal amino-acid
sequence present in PDE3A1 but not in PDE3A2, corresponding to
amino acid position 146 to 299 in SEQ ID NO:1.
118. The method of claim 111 or 112, wherein the polypeptide
comprises a sequence of amino acids present in both PDE3A1 and
PDE3A2 isoforms but having a different conformation in the two
isoforms.
119. The method of claim 111 or 112, wherein the polypeptide
comprises a sequence of amino acids present in both PDE3A1 and
PDE3A2 isoforms but having differential accessibility for
protein-protein interaction in the two isoforms.
120. The polypeptide of claim 119, wherein the sequence of amino
acids present in both PDE3A1 and PDE3A2 isoforms has greater
accessibility for protein-protein interactions in the PDE3A1
isoform than in the PDE3A2 isoform.
121. The method of claim 111 or 112, wherein the polypeptide
comprises a sequence of amino acids comprising a serine amino acid
that is differentially phosphorylated between PDE3A1 and PDE3A2
isoforms or a serine amino acid that is unique to PDE3A1 which
maybe phosphorylated.
122. The method of claim 121, wherein phosphorylation of the serine
amino acid in PDE3A1 isoform influences protein-protein
interactions.
Description
[0001] This patent application is a divisional application of U.S.
Ser. No. 14/800,657, filed Jul. 15, 2015, which claims the benefit
of the filing date of U.S. Ser. No. 62/024,994, filed Jul. 15,
2014, the contents of which are herein incorporated by reference in
their entirety into the present patent application.
[0003] Throughout this application various publications are
referenced. The disclosures of these publications in their
entireties are hereby incorporated by reference into this
application in order to more fully describe the state of the art to
which this invention pertains.
BACKGROUND OF THE INVENTION
[0004] PDE3 and the Regulation of Myocardial Contractility
[0005] Cyclic nucleotide phosphodiesterases regulate intracellular
signaling by hydrolyzing cAMP and/or cGMP. By blocking their
hydrolysis, phosphodiesterase inhibitors potentiate cyclic
nucleotide-mediated signaling. Eleven families of these enzymes
have been described.sup.1. Two subfamilies, PDE3A and PDE3B, have
been identified.sup.2,3. Myocardial contractility is regulated by
PDE3A, and Pde3a ablation in mice increases the phosphorylation of
two sarcoplasmic reticulum proteins involved in intracellular
Ca.sup.2+ cycling: phosphorylation of phospholamban (PL or PLB)
which stimulates the activity of the Ca.sup.2+-transporting ATPase
of the sarcoplasmic reticulum (SERCA2), increasing Ca.sup.2+ uptake
during diastole, and phosphorylation of ryanodine-sensitive
Ca.sup.2+ channels which increases Ca.sup.2+ release from the
sarcoplasmic reticulum during systole.sup.4-6 (FIG. 1). These
changes in protein phosphorylation augment myocardial contractility
by increasing the amplitude of intracellular Ca.sup.2+
transients.sup.6. The role of PDE3A in regulating Ca.sup.2+ uptake
by the sarcoplasmic reticulum is likely to be linked to its
integration into an intracellular signaling complex that includes
SERCA2, AKAP18, phospholamban and PKA.sup.6.
[0006] PDE3 Inhibition in Heart Failure
[0007] In dilated cardiomyopathy, decreases in myocardial
.beta.-adrenergic receptor density, together with increases in Gai
and .beta.-adrenergic receptor kinase activity, attenuate the
stimulation of adenylyl cyclase by catecholamines, leading to
decreases in myocardial cAMP content and intracellular Ca.sup.2+
transient amplitude.sup.7-16. PDE3 inhibitors are used to
`overcome` this reduction in intracellular cAMP content and
increase cAMP-mediated signaling in failing myocardium. In the
short term, PDE3 inhibitors raise cardiac output and lower left
ventricular filling pressures.sup.17-23. With long-term
administration, however, these benefits are outweighed by an
increase in sudden cardiac death.sup.24. While our knowledge
regarding the mechanisms is limited, they appear to be separate
from those that augment contractility: an increase in SERCA2
activity, the consequence of phospholamban phosphorylation (FIG.
1), has anti-arrhythmic effects in animal models of
ischemia/reperfusion and chronic heart failure.sup.25,26.
Pro-apoptotic consequences of PDE3 inhibition, though, are likely
to contribute to pathologic remodeling in dilated
cardiomyopathy.sup.27. PDE3 inhibition in rats and Pde3a ablation
in mice lead to increases in the phosphorylation of cAMP response
element-binding protein (CREB) and consequent increases in the
expression of inducible cAMP early repressors (ICER' s), promoting
apoptosis (FIG. 1).sup.6,28,29. Conversely, PDE3A overexpression in
mice reduces ICER, increases Bcl-2 expression and reduces apoptosis
following ischemia/reperfusion injury (but reduces myocardial
contractility).sup.30.
[0008] Alternative Pathways for cAMP-Mediated Protein
Phosphorylation
[0009] Until now, studies of the contractile and pro-apoptotic
effects of PDE3 inhibition have focused principally on substrates
of PKA, which is activated directly by cAMP. More recently, it has
become clear that the effects of cAMP are also mediated by
guanine-nucleotide-exchange proteins activated by cAMP (Epacs),
which influence protein phosphorylation through diverse mechanisms
(FIG. 2).sup.31,32. In cardiac myocytes, Epac activation augments
contractility through signaling pathways that increase the
phosphorylation of ryanodine-sensitive Ca.sup.2+ channels of the
sarcoplasmic reticulum by Ca.sup.2+/calmodulin-activated protein
kinase II (CamKII)--which was seen in pde3a.sup.-/- mice.sup.1--and
of sarcomeric proteins such as cardiac myosin-binding protein C and
troponin I by CamKII and protein kinase C (PKC).sup.32-36. Epac
activation also has pro-hypertrophic actions that result, at least
in part, from the activation of CamKII, as well as the protein
phosphatase calcineurin.sup.37,38. These observations indicate that
changes in intracellular cAMP are likely to affect the
phosphorylation of a large number of proteins that may contribute
to the beneficial and adverse effects of PDE3 inhibition. A recent
study of responses to .beta.-adrenergic receptor activation in
mouse embryonic fibroblast cells showed both increases and
decreases in protein phosphorylation.sup.39, and, in our
experiments, exposure of cultured cells to agents that stimulate
cAMP-mediated signaling resulted in both increases and decreases in
protein phosphorylation, covering both PKA and non-PKA sites.
Interactions between PDE3B and Epac have been identified in
vascular smooth muscle myocytes.sup.40, and peptides that disrupt
this interaction activate Epac and lead to the activation of
phosphoinositide-3-kinase-.gamma. (PI3K.gamma.), extracellular
signal-related kinase (ERK) and protein kinase B (PKB, also known
as Akt).sup.41, but the role of PDE3 in regulating Epac-mediated
protein phosphorylation in cardiac myocytes remains unexplored.
cAMP can also regulate L-type Ca.sup.2+ channels directly.sup.42,
and Epac activation induces other responses in addition to protein
phosphorylation.sup.31.
[0010] Individual Phosphodiesterases Regulate cAMP-Mediated
Signaling in Distinct Intracellular Compartments of Cardiac
Myocytes
[0011] In this context, it is noteworthy that cAMP content is
regulated differentially in spatially and functionally distinct
compartments of cardiac myocytes, a phenomenon referred to as the
`compartmentation` of cAMP-mediated signaling. It has long been
known that exposure to .beta.-adrenergic receptor agonists
increases cAMP content in cytosolic and microsomal fractions of
cardiac muscle and augments contractility, while exposure to
prostaglandin E1 (PGE1) increases cAMP content only in cytosolic
fractions, without inotropic effects.sup.43,44. This
compartmentation of cAMP-mediated signaling is altered in a rat
model of heart failure following a redistribution of
.beta.-adrenergic receptor subtypes within cell membranes.sup.45,
and is a feature of the pathophysiology of dilated cardiomyopathy
in humans (both ischemic and nonischemic), where the reduction in
cAMP content is much more pronounced in microsomes than in
cytosolic fractions (FIG. 3).sup.15.
[0012] Over the past decade, the prominent involvement of
phosphodiesterases in this compartmentation has become apparent. In
rat cardiac myocytes, .beta.-adrenergic receptor agonists induce
increases in intracellular cAMP content that are highly
localized.sup.46. Individual phosphodiesterases, which are targeted
by protein-protein interactions to specific intracellular domains,
have distinct roles. In rat heart, PDE4 has a greater role than
PDE3 in regulating glucagon and catecholamine-mediated increases in
intracellular cAMP content, while PDE3 has a greater role in
regulating forskolin-induced increases.sup.47,48. PDE2 has a major
role in regulating .beta.-adrenergic receptor-mediated increases in
intracellular cAMP content but only a small role in regulating
forskolin-induced increases, and PDE2 and PDE3 regulate `opposing`
effects of cGMP on cAMP-mediated signaling in rat heart in
functionally separate compartments.sup.49,50.
[0013] These studies focused on phosphodiesterase families, but
individual isoforms within a family have precise roles in specific
intracellular microdomains. This has been examined extensively in
the PDE4 family. PDE4D3 is present in multiprotein complexes
regulating KCNQ1/KCNE1 K.sup.+ channels and ryanodine-sensitive
Ca.sup.2+ channels.sup.51,52. The latter are hyperphosphorylated in
Pde4d.sup.-/- mice, leading to abnormalities of
sarcoplasmic-reticulum Ca.sup.2+ release associated with
arrhythmias and the development of dilated cardiomyopathy.sup.52.
In contrast, experiments in Pde4d.sup.-/- and Pde4b.sup.-/- mice
showed that the stimulation of L-type Ca.sup.2+ currents by
.beta.-adrenergic receptor agonists is controlled specifically by
PDE4B.sup.53. These unique roles for PDE4 variants derive
principally from the differences in their intracellular
localization, which in turn reflect the distinct protein-protein
interactions through which they are recruited to intracellular
signaling complexes with a range of proteins, including AKAP's,
.beta.-arrestins, Src, Lyn and Fyn.sup.54,55.
[0014] Multiple Isoforms of PDE3 are Expressed in Human
Myocardium
[0015] In human cardiac myocytes, the PDE3A gene gives rise,
through a combination of transcription and translation from
alternative sites, to several isoforms whose amino-acid sequences
are identical save for the presence of different lengths of
N-terminal sequence that are involved in intracellular
localization, protein-protein interactions and allosteric
regulation of catalytic activity, which resides in the C-terminus
(FIG. 4).sup.56. PDE3A1, a 136-kDa protein, has a unique N-terminal
extension containing hydrophobic loops that insert into
intracellular membranes.sup.57,58, and three known sites of
phosphorylation, S293, S312 and S428.sup.59-61. PDE3A2, a 118-kDa
protein transcribed from a downstream site in exon 1, lacks the
N-terminal extension and S293. PDE3A3, which is translated from a
downstream site in the PDE3A2 mRNA, is a 94-kDa protein that lacks
all of these phosphorylation sites. The PDE3B gene gives rise to a
single 146-kDa protein, whose domain organization resembles that of
PDE3A1. Its C-terminal catalytic region is highly homologous to
that of PDE3A1, and it contains an N-terminal hydrophobic sequence
and phosphorylation sites similar to two of the three sites
identified in PDE3A1.sup.62,63. In view of their C-terminal
sequence identity (for PDE3A1, PDE3A2 and PDE3A3) and homology
(PDE3B), all four isoforms are similar with respect to their basal
catalytic activity and sensitivity to existing PDE3
inhibitors.sup.64.
[0016] The Potential Opportunity and Its Clinical Impact
[0017] The American Heart Association estimates that 5.7 million
Americans have heart failure. Each year, >550,000 new cases are
diagnosed, among which .about.50% involve impaired contractility.
The annual hospitalization rate is >1 million, and annual
mortality is >270,000.sup.65,66. An agent that could inhibit
cardiac diseases such as hypertrophy and increase survival would
represent a major advance, and its clinical impact would be
immense. While the benefit might be greatest for patients with
advanced heart failure who are poor candidates for ventricular
assist devices, artificial hearts and heart transplantation--which
includes the ever-increasing population of aging patients with
comorbidities that are contraindications for surgery--a large
proportion of patients with NYHA class 3 or 4 symptoms could be
expected to benefit. Our discovery provides a novel approach to
this enormously important clinical problem.
SUMMARY OF THE INVENTION
[0018] The invention provides for an isolated or purified peptide,
polypeptide or peptidomimetic possessing anti-hypertrophic activity
in a cardiac myocyte. In one embodiment, the polypeptide may be a
mutant derived from wild-type PDE3A1 protein. The wild-type PDE3A1
protein may have the amino acid sequence given in SEQ ID NO:1 at
amino acid position 146 to 1141.
[0019] The invention also provides a peptidomimetic possessing an
anti-hypertrophic activity in a cardiac myocyte, wherein the
peptidomimetic mimics a structure or part of a structure formed by
a polypeptide derived from the amino terminus of wild-type PDE3A1
at amino acid position 146 to 668 in SEQ ID NO:1.
[0020] The invention further provides a peptidomimetic possessing
an anti-hypertrophic activity in a cardiac myocyte, wherein the
peptidomimetic mimics a structure or part of a structure formed by
an amino-terminal polypeptide present in wild-type PDE3A1 but not
in PDE3A3, corresponding to amino acid position 146 to 483 in SEQ
ID NO:1.
[0021] Additionally, the invention provides a peptidomimetic
possessing an anti-hypertrophic activity in a cardiac myocyte,
wherein the peptidomimetic mimics a structure or part of a
structure formed by an amino-terminal polypeptide present in
wild-type PDE3A1 but not in PDE3A2, corresponding to amino acid
position 146 to 299 in SEQ ID NO:1, or alternatively, the
peptidomimetic mimics a structure or part of a structure formed by
wild-type PDE3A1 from amino acid position 300 to 1141 in SEQ ID
NO:1, in which the structure or part of the structure is different
in PDE3A2; or alternatively, the peptidomimetic mimics a structure
or part of a structure having greater accessibility for
protein-protein interactions in wild-type PDE3A1 than in PDE3A2,
corresponding to amino acid position 300 to 1141 in SEQ ID NO:1; or
alternatively, the peptidomimetic mimics a structure or part of a
structure of phospho-PDE3A1 at a serine residue unique to PDE3A1
protein or phosphorylated selectively or differentially in
wild-type PDE3A1 and PDE3A2 proteins.
[0022] The invention also provides a polypeptide having the ability
to avoid pro-hypertrophic effect of conventional PDE3 inhibition in
a cardiac myocyte. In one embodiment, the polypeptide may be a
mutant variant derived from wild-type PDE3A1 protein and wherein
the wild-type PDE3A1 protein has the amino acid sequence given in
SEQ ID NO:1 at amino acid position 146 to 1141.
[0023] The invention further provides nucleic acid molecules
encoding a polypeptide possessing anti-hypertrophic activity in a
cardiac myocyte. In one embodiment, the nucleic acid molecule is
DNA (e.g., cDNA) or a hybrid thereof. Alternatively, the nucleic
acid molecule is RNA or a hybrid thereof.
[0024] Additionally, the invention provides a vector, which
comprises the nucleotide sequences of the invention. A host vector
system is also provided. The host vector system comprises the
vector of the invention in a suitable host cell. Examples of
suitable host cells include, but are not limited to, prokaryotic
and eukaryotic cells.
[0025] The invention also provides a peptidomimetic to avoid or
counter pro-hypertrophic effect of conventional PDE3 inhibition in
a cardiac myocyte, wherein the peptidomimetic mimics a structure or
part of a structure formed by a polypeptide derived from the amino
terminus of wild-type PDE3A1 at amino-acid position 146 to 668 in
SEQ ID NO:1.
[0026] The invention further provides a peptidomimetic to avoid or
counter pro-hypertrophic effect of conventional PDE3 inhibition in
a cardiac myocyte, wherein the peptidomimetic mimics a structure or
part of a structure formed by an amino-terminal polypeptide present
in wild-type PDE3A1 but not in PDE3A3, corresponding to amino acid
position 146 to 483 in SEQ ID NO:1.
[0027] The invention also provides a peptidomimetic to avoid or
counter pro-hypertrophic effect of conventional PDE3 inhibition in
a cardiac myocyte, wherein the peptidomimetic mimics a structure or
part of a structure formed by an amino-terminal polypeptide present
in wild-type PDE3A1 but not in PDE3A2, corresponding to amino acid
position 146 to 299 in SEQ ID NO:1; or alternatively, the
peptidomimetic mimics a structure or part of a structure formed by
wild-type PDE3A1 from amino acid position 300 to 1141 in SEQ ID
NO:1, in which the structure or part of the structure is different
in PDE3A2; or alternatively, the peptidomimetic mimics a structure
or part of a structure having greater accessibility for
protein-protein interactions in wild-type PDE3A1 than in PDE3A2,
corresponding to amino-acid position 300 to 1141 in SEQ ID NO:1; or
alternatively, the peptidomimetic mimics a structure or part of a
structure of phospho-PDE3A1 at a serine residue unique to PDE3A1
protein or differentially phosphorylated between wild-type PDE3A1
and PDE3A2 proteins.
[0028] The invention also provides methods of preventing,
inhibiting or reversing hypertrophy in a cardiac myocyte. The
method comprises contacting the cell with a peptide, polypeptide or
peptidomimetic of the invention.
[0029] The invention further provides methods of avoiding
pro-hypertrophic effect of conventional PDE3 inhibition in a
cardiac myocyte. The method comprises contacting the cell with a
peptide, polypeptide or a peptidomimetic of the invention.
[0030] The invention also provides methods for preventing,
inhibiting or reversing myocardial hypertrophy in a subject. The
method comprises administering to the subject a peptide,
peptidomimetic or small molecule that interacts with a
PDE3-interacting protein that affects myocardial hypertrophy in an
amount effective so as to prevent, inhibit or reverse myocardial
hypertrophy, thereby preventing, inhibiting or reversing myocardial
hypertrophy in a subject.
[0031] The invention also provides methods for obtaining a
beneficial effect of PDE3 inhibition in a subject with reduced or
no adverse effect, wherein the subject is treated with a PDE3
isoform-specific or isoform-selective inhibitor.
[0032] The invention further provides methods for increasing
selectivity of PDE3 inhibition in a cardiac myocyte, wherein such
method comprises contacting the cardiac myocyte with a peptide,
peptidomimetic or small molecule that interacts with a
PDE3-interacting protein selective for a PDE3 isoform, or
alternatively, contacting, expressing in or introducing in the
cardiac myocyte a catalytically compromised, reduced or inactive
form of a PDE3 isoform or its derivative, so as to selectively
inhibit the PDE3 isoform, thereby increasing selectivity of PDE3
inhibition in a cardiac myocyte.
[0033] The invention also provides methods for selectively
inhibiting a PDE3 isoform. The method comprises introduction or
expression of an altered or mutated version of the PDE3 isoform to
be selectively inhibited in a cell and wherein the altered or
mutated version of the PDE3 isoform has altered protein-protein
interaction or has altered or mutated catalytic activity.
[0034] Additionally, the invention provides methods for selectively
altering cAMP level within a cellular compartment. The method
comprises introduction or expression of an altered or mutated
version of a PDE3 isoform associated with the cellular compartment
and wherein the altered or mutated version of the PDE3 isoform has
altered protein-protein interaction or has altered or mutated
catalytic activity.
[0035] The invention also provides methods for eliciting positive
inotropic response in a subject without myocardial hypertrophy or
for eliciting positive inotropic and myocardial anti-hypertrophic
responses in a subject. The method comprises administering to the
subject any one of agents of the invention. The agents may be an
agent that selectively decreases PDE3A1 activity in a cardiac
myocyte; a peptide, a peptidomimetic or small molecule that mimics
PDE3A1 amino terminus; a peptide, peptidomimetic or small molecule
that interacts with a PDE3A1-interacting protein that selectively
affects cAMP level in the intracellular compartment associated with
PDE3A1 so as to increase Ca.sup.2+ uptake from cytosol to
sarcoplasmic reticulum during diastole and increase Ca.sup.2+
release from sarcoplasmic reticulum during systole; a gene therapy
vector for the delivery and/or expression of a catalytically
compromised, reduced or inactive PDE3A1 mutant gene so as to
selectively increase cAMP locally in an intracellular compartment
associated with endogenous PDE3A1 protein, thereby eliciting
positive inotropic response in a subject without myocardial
hypertrophy or for eliciting positive inotropic and myocardial
anti-hypertrophic responses in a subject.
BRIEF DESCRIPTION OF THE FIGURES
[0036] FIG. 1. Inotropic and pro-apoptotic actions of cAMP
regulated by PDE3A in cardiac myocytes. Phosphorylation of
membrane-associated proteins stimulates Ca.sup.2+ cycling by the
sarcoplasmic reticulum, while phosphorylation of transcription
factors stimulates ICER expression. (A-kinase anchoring
proteins--`AKAPs`--localize PKA to multiprotein complexes.)
[0037] FIG. 2. Alternative pathways for cAMP-mediated signaling.
Epac activation by cAMP leads to the activation of protein kinases
and phosphatases implicated in inotropic, pro-arrhythmic and
hypertrophic responses.
[0038] FIG. 3. Compartment-selective decrease in intracellular cAMP
content in failing human myocardium.
[0039] FIG. 4. PDE3 isoforms in cardiac myocytes.
[0040] FIG. 5. Anti-hypertrophic actions of PDE3A1-selective
targeting in neonatal rat ventricular myocytes. Conventional PDE3
inhibitors (e.g., cilostamide) promote myocyte hypertrophy (left).
Transfection with a dominant-negative PDE3A1 construct does not
promote hypertrophy, and blocks the hypertrophic responses to
norepinephrine (`NE`)(center). Transfection with a
dominant-negative PDE3A2 construct does not have this effect
(right).
[0041] FIG. 6A and FIG. 6B. PDE3A, SERCA2, PLB, AKAP18, co-localize
in the Z-bands in normal human myocardium. FIG. 6A. Cryostat
sections of normal human left ventricle were permeabilized and
incubated with rabbit anti-PDE3A-CT, anti-desmin, anti-SERCA2,
anti-PLB, anti-AKAP18 and anti-myomesin or the other indicated
primary antibodies, followed by incubation with alexa fluor.RTM.
488- or 594-conjugated anti-mouse or anti-rabbit secondary
antibodies. Signals were detected with a Zeiss LSM510 laser
scanning confocal microscope. Green fluorescence staining for PDE3A
(FIG. 6A); DAPI staining of nuclei (blue); Red fluorescent staining
for marker proteins: Desmin, PLB, SERCA2, AKAP18 and myomesin.
Fourth panel: merged images of PDE3A, marker proteins, and DAPI.
PDE3A exhibits a striated pattern and co-localizes with desmin,
SERCA2, PLB and AKAP18. FIG. 6B. Merged images from stacks of 10-15
sections (with 1 .mu.m intervals) reveal colocalization of PDE3A
with desmin, SERCA2, PLB, AKAP18, but not with myomesin (labeling
M-line Red). X-Y (center), above X-Z (top), and Y-Z (right) planes
are at indicated positions. Representative images from 3
independent experiments are shown.
[0042] FIG. 7A-F. cAMP, PKA, and PDE3-inhibition increase SERCA2
activity and Ca.sup.2+ uptake. FIG. 7A. After incubation of SR
fractions (20 .mu.g) in the absence or presence of the indicated
concentrations of ATP and/or cAMP, without or with cilostamide or
rolipram, endogenous PLB, phosphorylated PLB, and .beta.-actin were
detected after SDS-PAGE and immunoblotting. Data are representative
of three experiments. In these and other Western blots, PLB is
predominantly monomeric, most likely due to the heating of samples,
prior to electrophoresis, under reducing conditions (buffer
containing .beta.-mercatoethanol, DTT, and SDS). FIG. 7B. Bar graph
summarizing pSer16PLB/PLB total ratios. *P<0.01 vs. control (n=3
independent experiments). FIG. 7C. PDE activity in human cardiac SR
fractions, expressed as specific activity (pmol cAMP
hydrolyzed/min/mg). Results are presented as mean+/-SEM (n=3
preparations). PDE3 activity was determined as the
cilostamide-sensitive fraction, and PDE4 activity as the
rolipram-sensitive fraction. PDE3 activity is significantly higher
than PDE4 activity (*P<0.001). FIG. 7D. After incubation of SR
fractions without or with the indicated concentrations of cAMP
(0-10 .mu.M), .sup.45Ca.sup.2+ uptake was measured in the presence
of 0.5 .mu.M free Ca.sup.2+. Results are presented as % increase
due to cAMP, with basal Ca.sup.2+ uptake (9.4+/-0.8 nmol/mg/min,
n=3) taken as 100%. FIG. 7E. After incubation of SR fractions with
or without cAMP (3 .mu.M) in the presence or absence of cilostamide
(1 .mu.M), 45Ca.sup.2+ uptake was assayed as described above.
Results are presented as mean+/-SE (n=3). FIG. 7F. Ca.sup.2+ uptake
(Upper panel) and SERCA activity (Lower panel) were assayed in the
presence or absence of rPKAc. Results are presented as nmol
(Ca.sup.2+ or P.sub.i)/min/mg (mean+/-SE) (n=3).
[0043] FIG. 8A-D. Detection of PDE3A isoforms by Superose 6 (S6)
gel-filtration chromatography of solubilized human myocardial
membrane or cytosolic fractions. Solubilized myocardial membranes
(FIG. 8A) and cytosolic fractions (FIG. 8B) were prepared (3 mg
protein, 1 ml) and subjected to chromatography on S6 columns. Upper
Panels: Portions (10 .mu.l) of fractions (0.5 ml) were assayed for
PDE3 activity (.tangle-solidup.) (pmol cAMP hydrolysed/min/0.5 ml)
and protein content [AU (absorption units) 280 nm]
(.circle-solid.). Molecular mass standard peaks are indicated: 1,
thyroglobulin (670 kDa); 2, .gamma.-globulin (158 kDa); 3,
ovalbumin (44 kDa); 4, myoglobin (17 kDa); 5, vitamin B12 (1.35
kDa). Bottom panels: Portions (20 .mu.l) of indicated fractions
were subjected to SDS/PAGE and immunoblotted with anti-PDE3A
antibodies as indicated. One representative experiment is shown
(n=3). (FIG. 8C) Pooled HMW and LMW peaks (Lower panels of FIGS. 7A
and 7B) were subjected to immunoprecipitation with anti-PDE3A
antibody, and immunoblotted with anti-phospho-PKA-substrate (Upper
panel) and anti-PDE3A (Lower panel) antibodies. Bar graph (Right
panel) summarizing pPDE3A1/PDE3A1 (p3A1/3A1) and pPDE3A2/PDE3A2
(p3A2/3A2) ratios in HMW and LMW peaks; .apprxeq.10-fold increase
in phosphorylation of PDE3A1 and .about.5 fold increase in
phosphorylation of PDE3A2 in HMW peaks compared to LMW peaks
(*p<0.01). Results are representative of 3 individual
experiments. (FIG. 8D) PDE3A was immunoprecipitated from
solubilized myocardial membranes and incubated, as indicated, with
or without 250 units of rPKAc in the presence of 200 .mu.M ATP and
5 mM MgCl2 in phosphorylation buffer, supplemented with (Upper
panel) or without (Lower panel) [.gamma.-.sup.32P] ATP, as
described in methods. rPKAc plus 10 uM PKI-tide (PKAc inhibitor)
was also used as a control. Upper panel: The reaction products were
subjected to SDS-PAGE and, after phosphoimager scanning of the wet
gels, for detection of .sup.32P-PDE3A. Middle panel: PDE3A isoforms
were identified by Western blotting. Lower panel: PDE3 activity was
assayed in PDE3A immunoprecipitates incubated with or without rPKAc
and PKI in the absence of [.gamma.-.sup.32P] ATP. Results are
expressed as pmol cAMP hydrolyzed/min. Shown are representative
data from 3 independent experiments.
[0044] FIG. 9. rPKAc increases interaction of PDE3A with signaling
molecules in Superose 6 LMW-fractions of solubilized human
myocardial membranes. Solubilized myocardial membranes (3 mg
protein, 1 ml) were subjected to chromatography on S6 columns as
described in FIG. 7A and fractionated into LMW and BMW fractions.
LMW fractions were pooled from two different experiments (FIG. 7A),
and concentrated via centriprep YM-3 (centrifugal filter unit with
Ultracel-3 membrane, >3 Kd: nominal molecular weight limit).
Upper Panels: Pooled and concentrated S6 membrane LMW fractions
were split, incubated without or with rPKAc in phosphorylation
buffer with 200 .mu.M ATP and 5 mM MgCl.sub.2 for 1 h at 30.degree.
C., and re-chromatographed on S6-column. Portions (10 .mu.l) of
fractions (0.5 ml) were assayed for PDE3 activity
(.tangle-solidup.) (pmol cAMP hydrolysed/ min/0.5 ml) and protein
content [AU (absorption units) 280 nm] (.circle-solid.). Molecular
mass standards: 1. thyroglobulin (670 kDa); 2. .gamma.-globulin
(158 kDa); 3. ovalbumin (44 kDa); 4. myoglobin (17 kDa); 5. vitamin
B12 (1.35 kDa). Bottom panels: Portions (20 .mu.l) of indicated
fractions were subjected to SDS/PAGE and immunoblotted with
antibodies as indicated. Representative results from one of two
independent experiments are shown.
[0045] FIG. 10. rPKAc promotes interactions of PDE3A with
components of the SERCA2 regulatory signalosome. Solubilized
myocardial membranes were prepared (3 mg protein, 1 ml) and
subjected to chromatography on S6 columns as in FIG. 7A. Membrane
LMW fractions were pooled from two different experiments (FIG. 7A),
and concentrated via centriprep YM-3 (Centriprep centrifugal filter
unit with Ultracel-3 membrane). Pooled, concentrated fractions were
split and incubated without or with rPKAc in phosphorylation buffer
with 200 .mu.M ATP and 5 mM MgCl.sub.2for 1 h at 30.degree. C. The
fractions were incubated with anti-PDE3A-CT (10 .mu.g) or
non-immune IgG (10 .mu.g) (overnight, 4.degree. C.), and
immunoprecipitated using Protein-G sepharose. Protein
G-sepharose-bound proteins were eluted by boiling in 200 .mu.l of
Laemmli's sample buffer. Samples (15 .mu.l) were subjected to
SDS/PAGE and immunoblotted with specific antibodies as shown. Input
membrane proteins (10 .mu.g) were also loaded on the gels as
positive controls. Representative results from three independent
experiments are shown. Similar amounts of PDE3A were
immunoprecipited in the control group and in reactions incubated
with rPKAc. Band intensities of immunoprecipitated PDE3A and its
interacting signaling molecules were analyzed using LAS3000
analyzer and presented as binding percentage ratios of signaling
molecules (rPKAc/control). For PDE3A, band intensities of
pPDEA1/pPDE3A2/pPDE3A3 in PKAc/control percentage ratios were
calculated. *P<0.01 vs control (n=3 independent
experiments).
[0046] FIG. 11A-D. rPKAc phosphorylates rhPDE3A and increases its
interactions rSERCA2. FIG. 11A. Schemes representing PDE3A1 [NHR1:
trans-membrane domain (obligatory membrane insertion domain); NHR2:
membrane association domain; CCR: conserved C-terminal catalytic
region; P1-4: predicted PKA phosphorylation sites; rhPDE3A and
truncated mutants (PDE3A2, PDE3A-.DELTA.510, PDE3A-RD), and rSERCA2
(1042 amino acids, 3-77 cation transporter N-terminal; 93-341,
E1-E2 ATPase; 345-724, haloacid dehydrogenase like hydrolase;
819-991, cation transporter ATPase C-terminus). FIG. 11B. Putative
PKA phosphorylation sites of PDE3A designated with asterisks. FIG.
11C-D. Purified rSERCA2 (150 ng) (Abnova) and 50 units of
Flag-tagged rhPDE3A1 truncated mutants [rhPDE3A2,
rhPDE3A-.DELTA.510, and similarly expressed rhPDE3A-RD (aa
146-484)] (FIG. 11D) or mutants lacking the PKA putative
phosphorylation site mutants of rhPDE3A1 [Ser292/293A (M1), S312A
(M2), S428A (M3), S438A (M4), S292A/293A/312A/438A (M5)] (FIG. 11C)
were incubated with or without 50 units of rPKAc at 30.degree. C.
for 30 min and 5 mM MgCl.sub.2 in phosphorylation buffer. Proteins
were immunoprecipitated with anti-Flag antibodies and immunoblotted
with anti-SERCA2 (upper panel), or anti-Flag (middle panel). Lower
panel: input control (SERCA2). Shown are representative blots from
three independent experiments. (RD: regulatory domain; AA: amino
acid).
[0047] FIG. 12A-C. rPKAc induced phosphorylation of rhPDE3A induces
interaction with rat rAKAP18.delta.. (FIG. 12A). Schemes
representing PDE3A1 [NHR1: trans-membrane domain (obligatory
membrane insertion domain); NHR2: membrane association domain; CCR:
conserved C-terminal catalytic region]; rAKAP18.delta. with Rh
binding site from amino acid (aa) 301-314 and a unique N-terminus
from aa 1-26. FIG. 12B-C. His tagged rAKAP18.delta. (100 ng) and 50
units of Flag-tagged rhPDE3A1 were incubated with different
concentrations of rPKAc (FIG. 12B), or without or with 50 units of
rPKAc and 200 .mu.M ATP at 30.degree. C. in phosphorylation buffer
(FIG. 12C). Immunoprecipitated proteins and input were
immunoblotted with anti-Flag and anti-AKAP18-his antibodies as
indicated. Similar amounts of AKAP18.delta. were immunoprecipited
in the control groups and in reactions incubated with rPKAc. (FIG.
12C) Bar graph summarizing binding of PDE3A with AKAP18.delta. in
the absence (control) and presence of rPKAc. Ratios of rhPDE3A
bound to rAKAP18.delta. were calculated without (Control, C) or
with rPKAc; .about.9-fold increase in binding of rhPDE3A with
AKAP18.delta. in the presence of rPKAc (*p<0.001). Shown are
representative blots from three independent experiments.
[0048] FIG. 13A-C. Model of the regulation of SERCA2 activity by
cAMP and the AKAP18 and PLB-containing signalosome. FIG. 13A.
Components of the AKAP18/SERCA2/PLB complex are shown. FIG. 13B. In
the absence of cAMP, SERCA2 is inhibited by its interaction with
PLB. Activation of PKA by cAMP results in the phosphorylation of
PLB and PDE3A. The former dissociates from SERCA2, increasing
SERCA2's activity, but the integration of phosphorylated PDE3A into
the complex limits this effect by increasing hydrolysis of cAMP.
PP1 and PP2A in the complex would be expected to catalyze the
dephosphorylation of PDE3A, PLB and other PKA substrates, and
return the SERCA2 complex to its basal state. FIG. 13C. PDE3
inhibition potentiates the effect of cAMP on SERCA2.
DETAILED DESCRIPTION OF THE INVENTION
[0049] In its various aspects, the present invention provides
peptides, polypeptides, protein, and/or peptidomimetics that are
specific or selective inhibitors of wild-type or endogenous PDE3A1,
antibodies that specifically recognize and bind them, nucleic acid
molecules that encode them, recombinant DNA molecules, transformed
host cells, generation methods, assays, methods, and
compositions.
Compositions of the Invention
[0050] Conventional PDE3 inhibitors increase cardiac contractility,
but adversely affect survival, through mechanisms that remain
uncertain. Our invention involves e.g., selectively targeting PDE3
isoforms through mechanisms other than catalytic site inhibition
that are likely to involve interfering with the protein-protein
interactions of these isoforms so as to avoid the adverse
consequences of conventional PDE3 inhibitors and to provide
additional beneficial actions such as blocking pathologic
hypertrophic responses.
[0051] In an embodiment of the invention, we generated
catalytically-inactive forms of PDE3A1 and PDE3A2 as `dominant
negatives` to affect hypertrophic responses to beta-adrenergic
receptor stimulation in neonatal rat ventricular myocytes. Like
catalytic-site inhibition with cilostamide, expression of the
PDE3A2 dominant negative promotes hypertrophy in these cells, and
has no opposing effect on hypertrophic responses to norepinephrine.
In contrast, expression of the PDE3A1 dominant negative has no
pro-hypertrophic effect, and actually blocks the hypertrophic
responses to norepinephrine. This latter finding indicates that
selectively targeting PDE3 isoforms through mechanisms other than
catalytic-site inhibition (these other mechanisms are likely to
involve interfering with the protein-protein interactions of these
isoforms) can avoid the adverse consequences of conventional PDE3
inhibitors, and can have additional beneficial actions such as
blocking pathologic hypertrophic responses.
[0052] The invention provides for an isolated or purified peptide,
polypeptide or peptidomimetic possessing anti-hypertrophic activity
in a cardiac myocyte by specifically or selectively inhibiting
wild-type or endogenous PDE3A1. In one embodiment, the polypeptide
may be a mutant derived from wild-type PDE3A1 protein. The
wild-type PDE3A1 protein may have the amino acid sequence given in
SEQ ID NO:1. In one embodiment, the wild-type PDE3A1 protein has
the amino acid sequence given in SEQ ID NO:1 at about amino acid
position 146 to 1141.
[0053] As used herein, the term "isolated" or "purified" in
reference to a peptide, polypeptide or peptidomimetic of the
invention does not require absolute purity and is substantially
free of impurities, e.g., interfering materials that inhibit the
function of a peptide, polypeptide or peptidomimetic of the
invention.
[0054] In one embodiment, the composition comprises isolated
polypeptide or an equivalent, derivative or analog thereof having 7
or more amino acid sequences of PDE3A1, wherein the composition is
substantially free of polypeptide or an equivalent, derivative or
analog thereof of non-PDE3A1.
[0055] In one embodiment, the composition comprises isolated
polypeptide or an equivalent, derivative or analog thereof having
10 or more amino acid sequences of PDE3A1, wherein the composition
is substantially free of polypeptide or an equivalent, derivative
or analog thereof of non-PDE3A1.
[0056] In one embodiment, the composition comprises isolated
polypeptide or an equivalent, derivative or analog thereof having
20 or more amino acid sequences of PDE3A1, wherein the composition
is substantially free of polypeptide or an equivalent, derivative
or analog thereof of non-PDE3A1.
[0057] In one embodiment, the mutant derived from wild-type PDE3A1
protein may be a catalytically compromised mutant of PDE3A1
protein. In another embodiment, the catalytically compromised
mutant of PDE3A1 protein may be a catalytically inactive mutant of
PDE3A1 protein or a catalytically reduced mutant of PDE3A1 protein
which may be a result of a mutation affecting tyrosine-751 (Y751),
histidine-836 (H836), histidine-840 (H840), glutamic acid-866
(E866), aspartic acid-950 (D950), or phenylalanine-1004 (F1004). In
a preferred embodiment, the catalytically inactive mutant of PDE3A1
protein has a mutation at phenylalanine-1004 (F1004).
[0058] In one embodiment, the mutation may be an amino acid change
to an alanine. In another embodiment, the mutation may be an amino
acid change to any amino acid other than an alanine. The amino acid
change may be glycine, serine, threonine, cysteine, valine,
leucine, isoleucine, methionine, proline, tyrosine, tryptophan,
phenylalanine, aspartic acid, glutamic acid, asparagine, glutamine,
histidine, lysine or arginine, and not an amino acid present in the
wild-type PDE3A1 at a position to be mutated.
[0059] In a preferred embodiment, the catalytically inactive mutant
of PDE3A1 protein has a mutation at phenylalanine-1004 to an
alanine (F1004A) with the amino acid sequence given in SEQ ID NO:2.
In one embodiment, the catalytically inactive mutant of PDE3A1
protein has the amino-acid sequence given in SEQ ID NO:2 at about
amino acid position 146 to 1141.
[0060] In another embodiment, the mutant derived from wild-type
PDE3A1 protein may be a deletion mutant of PDE3A1 protein. In
another embodiment, the deletion mutant of PDE3A1 protein lacks an
intact C-terminal catalytic region. In a further embodiment, the
deletion mutant of PDE3A1 protein may comprise an amino-terminal
sequence without the C-terminal catalytic region.
[0061] In a further embodiment, the polypeptides of the invention
may further comprising a mutation or multiple mutations in which
amino acid corresponding to serine-292, serine-293 and/or
serine-294 as provided in SEQ ID NO:1 are substituted with aspartic
acid, glutamic acid or combination of aspartic acid and glutamic
acid. In yet a further embodiment of the polypeptides of the
invention, the mutation of serine-292, serine-293 and/or serine-294
permits association with SERCA2 protein.
[0062] In yet another embodiment, the C-terminal catalytic region
may be given in SEQ ID NO:1 at about amino acid position 669 to
1108. In another embodiment, the amino-terminal sequence may
comprise ten or more amino acids having a sequence identical or
homologous to a sequence at about amino acid position 146 to 668 in
SEQ ID NO:1. In another embodiment, the amino-terminal sequence may
comprise ten or more amino acids having a sequence identical or
homologous to a sequence in the N-terminal amino-acid sequence
present in PDE3A1 but not in PDE3A3, corresponding to about amino
acid position 146 to 483 in SEQ ID NO:1. In yet another embodiment,
the amino-terminal sequence may comprise ten or more amino acids
having a sequence identical or homologous to a sequence in the
N-terminal amino-acid sequence present in PDE3A1 but not in PDE3A2,
corresponding to about amino acid position 146 to 299 in SEQ ID
NO:1. In one embodiment, the source of PDE3A homologs is mammalian
organisms.
[0063] In an embodiment, the polypeptide comprises a sequence of
amino acids present in both PDE3A1 and PDE3A2 isoforms but having a
different conformation in the two isoforms. In one embodiment, the
different conformation is a difference in the secondary structure
for a sequence of amino acid present in both PDE3A1 and PDE3A2
isoforms. In another embodiment, the different conformation is a
difference in the tertiary structure for a sequence of amino acid
present in both PDE3A1 and PDE3A2 isoforms.
[0064] In another embodiment, the polypeptide may comprise a
sequence of amino acids present in both PDE3A1 and PDE3A2 isoforms
but having differential accessibility for protein-protein
interaction in the two isoforms. The sequence of amino acids
present in both PDE3A1 and PDE3A2 isoforms may have greater
accessibility for protein-protein interactions in the PDE3A1
isoform than in the PDE3A2 isoform.
[0065] In yet another embodiment, the polypeptide may comprise a
sequence of amino acids comprising a serine amino acid which is
differentially phosphorylated between PDE3A1 and PDE3A2 isoforms.
Phosphorylation of the serine amino acid in PDE3A1 isoform may
influence protein-protein interactions. In one embodiment, the
serine amino acid that is unique to PDE3A1 which may be
phosphorylated is serine-292, serine-293 and/or serine-294. The
phosphorylation of the serine amino acid in PDE3A1 isoform may
influence protein-protein interaction such as the association of
PDE3A1 protein with SERCA2 protein.
[0066] Human homologues of PDE3A, naturally occurring allelic
variants of PDE3A and genomic PDE3A sequences may share a high
degree of homology to the mouse PDE3A sequences herein described.
In general, such nucleic acid molecules will hybridize to the human
PDE3A sequence under stringent conditions. Such sequences will
typically contain at least 70% homology, preferably at least 80%,
most preferably at least 90% homology to the mouse PDE3A
sequence.
[0067] In an embodiment, PDE3A1 and PDE3A2 isoforms may have a
common amino-acid sequence corresponding to about amino acid
position 300 to 1141 in SEQ ID NO:1.
[0068] In another embodiment, the serine amino acid may be any
serine in the polypeptide corresponding to about amino acid
position 300 to 1141 in SEQ ID NO:1.
[0069] In an embodiment, the mutant variant derived from wild-type
PDE3A1 protein may be a fusion or chimeric protein with a
compromised, reduced or inactive catalytic activity. The
compromised, reduced or inactive catalytic activity may be a
phosphodiesterase activity. The phosphodiesterase activity is
hydrolysis of cAMP and/or cGMP to 5'-AMP and/or 5'GMP,
respectively.
[0070] The invention also provides a peptidomimetic possessing an
anti-hypertrophic activity in a cardiac myocyte. The peptidomimetic
mimics a structure or part of a structure formed by a polypeptide
derived from the amino terminus of wild-type PDE3A1 at about
amino-acid position 146 to 668 in SEQ ID NO:1. In one embodiment,
the peptidomimetic mimics a structure or part of a structure formed
by an amino-terminal polypeptide present in wild-type PDE3A1 but
not in PDE3A3, corresponding to about amino acid position 146 to
483 in SEQ ID NO:1. In another embodiment, the peptidomimetic
mimics a structure or part of a structure formed by an
amino-terminal polypeptide present in wild-type PDE3A1 but not in
PDE3A2, corresponding to about amino acid position 146 to 299 in
SEQ ID NO:1. Alternatively, the peptidomimetic mimics a structure
or part of a structure formed by wild-type PDE3A1 from e.g., about
amino acid position 300 to 1141 in SEQ ID NO:1, in which the
structure or part of the structure is different in PDE3A2. The
structure or part of the structure of interest is one in which an
amino acid sequence present in both wild-type PDE3A1 and PDE3A2
isoforms forms different structures depending on whether the amino
acid sequence is present within the context of a PDE3A1 isoform or
a PDE3A2 isoform; the peptidomimetic will mimic the structure in
PDE3A1 isoform associated with this stretch of amino acid sequence.
In one embodiment, the structure of part of the structure is a
secondary structure. In a related embodiment, the structure of part
of the structure is a tertiary structure. Alternatively, the
peptidomimetic mimics a structure or part of a structure having
greater accessibility for protein-protein interaction in wild-type
PDE3A1 than in PDE3A2, corresponding to about amino-acid position
300 to 1141 in SEQ ID NO:1. Alternatively, the peptidomimetic
mimics a structure or part of a structure of phospho-PDE3A1 at a
serine residue unique to PDE3A1 protein or phosphorylated
selectively or differentially in wild-type PDE3A1 and PDE3A2
proteins.
[0071] The invention also provides a polypeptide having the ability
to avoid pro-hypertrophic effect of conventional PDE3 inhibition in
a cardiac myocyte. In one embodiment, the polypeptide may be a
mutant variant derived from wild-type PDE3A1 protein. The wild-type
PDE3A1 protein has the amino acid sequence given in SEQ ID NO:1 at
about amino acid position 146 to 1141.
[0072] Inhibition of PDE3 activity can refer to either inhibition
of catalytic activity or protein-protein interactions, including
protein-protein interactions that lead to post-translational
modification, such as phosphorylation. Conventional PDE3 inhibitors
target the phosphodiesterase activity of the catalytic domain of
two or more PDE3 family members (PDE3A1, PDE3A2, PDE3A3 and PDE3B).
As such, conventional PDE3 inhibition does not result in the
inhibition of a single PDE3 isoform but rather affects more than
one isoforms if not all PDE3 family members. Conventional PDE3
inhibition is associated with cardiac myocyte hypertrophy. In
contrast to conventional PDE inhibitors, isoform-specific or
isoform-selective inhibitor of the invention targets specific PDE3
isoform (such as PDE3A1 isoform) to inhibit protein-protein
interaction of the native PDE3 isoform targeted and as shown in
subject's invention produce beneficial effect, such as
anti-hypertrophy in cardiac myocyte.
[0073] In one embodiment, the polypeptide of the invention is
isolated or purified polypeptide.
[0074] In one embodiment, the mutant variant derived from wild-type
PDE3A1 protein may be a catalytically compromised mutant of PDE3A1
protein. The catalytically compromised mutant of PDE3A1 protein may
be a catalytically inactive mutant of PDE3A1 protein or a
catalytically reduced mutant of PDE3A1 protein. In another
embodiment, the catalytically compromised, reduced or inactive
mutant of PDE3A1 protein may be a result of a mutation affecting
tyrosine-751 (Y751), histidine-836 (H836), histidine-840 (H840),
glutamic acid-866 (E866), aspartic acid-950 (D950) or
phenylalanine-1004 (F1004). In a preferred embodiment, the
catalytically inactive mutant of PDE3A1 protein may be a mutation
at phenylalanine-1004 (F1004).
[0075] In one embodiment, the mutant variant derived from wild-type
PDE3A1 protein or mutant PDE3A1 protein of the invention is an
isolated or purified protein.
[0076] The invention further provides nucleic acid molecules
encoding a polypeptide possessing anti-hypertrophic activity in a
cardiac myocyte. In one embodiment, the nucleic acid molecule is
DNA (e.g., cDNA) or a hybrid thereof. Alternatively, the nucleic
acid molecule is RNA or a hybrid thereof.
[0077] Additionally, the invention provides a vector, which
comprises the nucleotide sequences of the invention. A host vector
system is also provided. The host vector system comprises the
vector of the invention transfected or introduced in a suitable
host cell. Examples of suitable host cells include, but are not
limited to, prokaryotic and eukaryotic cells.
[0078] The invention also provides a peptidomimetic to avoid or
counter pro-hypertrophic effects of conventional PDE3 inhibition
(i.e., inhibition of the catalytic activity of PDE3) in a cardiac
myocyte. The peptidomimetic mimics a structure or part of a
structure formed by a polypeptide derived from the amino terminus
of wild-type PDE3A1 at about amino acid position 146 to 668 in SEQ
ID NO:1. In one embodiment, the peptidomimetic mimics a structure
or part of a structure formed by an amino-terminal polypeptide
present in wild-type PDE3A1 but not in PDE3A3, corresponding to
about amino acid position 146 to 483 in SEQ ID NO:1. In another
embodiment, the peptidomimetic mimics a structure or part of a
structure formed by an amino-terminal polypeptide present in
wild-type PDE3A1 but not in PDE3A2, corresponding to about amino
acid position 146 to 299 in SEQ ID NO:1. Alternatively, the
peptidomimetic mimics a structure or part of a structure formed by
wild-type PDE3A1 from about amino acid position 300 to 1141 in SEQ
ID NO:1, in which the structure or part of the structure is
different in PDE3A2. The structure or part of the structure of
interest is one in which an amino acid sequence present in both
wild-type PDE3A1 and PDE3A2 isoforms forms different structures
depending on whether the amino acid sequence is present within the
context of a PDE3A1 isoform or a PDE3A2 isoform; the peptidomimetic
will mimic the structure in PDE3A1 isoform associated with this
stretch of amino acid sequence.
[0079] Alternatively, the peptidomimetic mimics a structure or part
of a structure having greater accessibility for protein-protein
interactions in wild-type PDE3A1 than in PDE3A2, corresponding to
about amino acid position 300 to 1141 in SEQ ID NO:1.
Alternatively, the peptidomimetic mimics a structure or part of a
structure of phospho-PDE3A1 at a serine residue unique to PDE3A1
protein or differentially phosphorylated between wild-type PDE3A1
and PDE3A2 proteins.
[0080] In one embodiment, the peptidomimetic of the invention is
isolated or purified peptidomimetic.
[0081] Nucleic Acid Molecules that Encode Peptides and/or
Polypeptides that Specifically or Selectively Inhibit PDE3A1
[0082] Another aspect of the invention provides nucleic acid
molecules encoding the peptides or polypeptides that specifically
or selectively inhibit PDE3A1 of the invention, preferably in
isolated form, including DNA, RNA, DNA/RNA hybrid, and related
molecules, nucleic acid molecules complementary to the PDE3A1
coding sequence or a part thereof, and those which hybridize to the
nucleic acids encoding peptides and/or polypeptides that
specifically or selectively inhibit PDE3A1. Specifically
contemplated are genomic DNA, cDNAs, ribozymes, and antisense
molecules, as well as nucleic acids based on an alternative
backbone or including alternative bases, whether derived from
natural sources or synthesized.
[0083] For example, antisense molecules can be RNAs or other
molecules, including peptide nucleic acids (PNAs) or non-nucleic
acid molecules such as phosphorothioate derivatives, that
specifically bind DNA or RNA in a base pair-dependent manner. A
skilled artisan can readily obtain these classes of nucleic acid
molecules using the herein described PDE3A1 amino acid
sequences.
[0084] Embodiments of the nucleic acid molecules of the invention
include primers, which allow the specific amplification of nucleic
acid molecules of the invention or of any specific parts thereof,
and probes that selectively or specifically hybridize to nucleic
acid molecules of the invention or to any part thereof. The nucleic
acid probes can be labeled with a detectable marker. Examples of a
detectable marker include, but are not limited to, a radioisotope,
a fluorescent compound metal chelator or an enzyme. Technologies
for generating DNA and RNA probes are well known.
[0085] As used herein, a nucleic acid molecule is said to be
"isolated" when the nucleic acid molecule is substantially
separated from contaminant nucleic acid molecules that encode
polypeptides other than those that encode peptides or polypeptides
that specifically or selectively inhibit PDE3A1.
[0086] The peptide, polypeptide or peptidomimetic of the invention
may be formulated in a pharmaceutical composition further
comprising a pharmaceutically acceptable carrier.
[0087] The phrase "pharmaceutically acceptable carrier" refers to
any carrier known to those skilled in the art to be suitable for
the particular mode of administration. In addition, the peptide,
polypeptide or peptidomimetic of the invention may be formulated as
the sole pharmaceutically active ingredient in the composition or
may be combined with other active ingredients.
[0088] Compositions herein comprise one or more peptide,
polypeptide or peptidomimetic of the invention. The peptide,
polypeptide or peptidomimetic are, in one embodiment, formulated
into suitable pharmaceutical preparations such as solutions,
suspensions, tablets, dispersible tablets, pills, capsules,
powders, sustained release formulations or elixirs, for oral
administration or in sterile solutions or suspensions for
parenteral administration, as well as transdermal patch preparation
and dry powder inhalers. In one embodiment, the peptide,
polypeptide or peptidomimetic described above are formulated into
pharmaceutical compositions using techniques and procedures well
known in the art (see, e.g., Ansel Introduction to Pharmaceutical
Dosage Forms, Fourth Edition 1985, 126).
[0089] In one embodiment, the compositions may be formulated for
single dosage administration. To formulate a composition, the
peptide, polypeptide or peptidomimetic is dissolved, suspended,
dispersed or otherwise mixed in a selected carrier at an effective
concentration in an amount such that the treated condition may be
relieved, prevented, or one or more symptoms are ameliorated.
[0090] The active compound (e.g., peptide, polypeptide or
peptidomimetic of the invention) is included in the
pharmaceutically acceptable carrier in an amount sufficient to
exert a therapeutically useful effect in the absence of undesirable
side effects on the patient treated. The therapeutically effective
concentration may be determined empirically by testing the
compounds in in vitro and in vivo systems known in the art, and
then extrapolated therefrom for dosages for subjects such as
humans.
[0091] The active ingredient may be administered at once, or may be
divided into a number of smaller doses to be administered at
intervals of time. It is understood that the precise dosage and
duration of treatment is a function of the disease being treated
and may be determined empirically using known testing protocols or
by extrapolation from in vivo or in vitro test data. It is to be
noted that concentrations and dosage values may also vary with the
severity of the condition to be alleviated. It is to be further
understood that for any particular subject, specific dosage
regimens should be adjusted over time according to the individual
need and the professional judgment of the person administering or
supervising the administration of the compositions, and that the
concentration ranges set forth herein are exemplary only and are
not intended to limit the scope or practice of the claimed
compositions.
[0092] The pharmaceutical compositions may be provided for
administration to humans and animals in unit dosage forms, such as
tablets, capsules, pills, powders, granules, sterile parenteral
solutions or suspensions, and oral solutions or suspensions, and
oil-water emulsions containing suitable quantities of the compounds
or pharmaceutically acceptable derivatives thereof. The
pharmaceutically therapeutically active compounds and derivatives
thereof are, in one embodiment, formulated and administered in
unit-dosage forms or multiple-dosage forms. Unit-dose forms as used
herein refers to physically discrete units suitable for human and
animal subjects and packaged individually as is known in the art.
Each unit-dose contains a predetermined quantity of the
therapeutically active compound sufficient to produce the desired
therapeutic effect, in association with the required pharmaceutical
carrier, vehicle or diluent. Examples of unit-dose forms include
ampoules and syringes and individually packaged tablets or
capsules. Unit-dose forms may be administered in fractions or
multiples thereof. A multiple-dose form is a plurality of identical
unit-dosage forms packaged in a single container to be administered
in segregated unit-dose form. Examples of multiple-dose forms
include vials, bottles of tablets or capsules or bottles of pints
or gallons. Hence, multiple dose form is a multiple of unit-doses
which are not segregated in packaging.
[0093] Actual methods of preparing such dosage forms are known, or
will be apparent, to those skilled in this art; for example, see
Remington's Pharmaceutical Sciences, Mack Publishing Company,
Easton, Pa., 15th Edition, 1975.
[0094] Dosage forms or compositions containing active ingredient in
the range of 0.005% to 100% (wt %) with the balance made up from
non-toxic carrier may be prepared. Methods for preparation of these
compositions are known to those skilled in the art. The
contemplated compositions may contain 0.005%-100% (wt %) active
ingredient, in one embodiment 0.1-95% (wt %), in another embodiment
75-85% (wt %).
[0095] Combination Therapy
[0096] In another embodiment, the compositions may be administered
in combination, or sequentially, with another therapeutic agent.
Such other therapeutic agents include those known for treatment,
prevention, or amelioration of one or more symptoms of diseases and
disorders described herein.
Methods of the Invention
[0097] The invention also provides methods for preventing,
inhibiting or reversing hypertrophy in a cardiac myocyte. The
method comprises contacting the cell with a peptide, polypeptide or
peptidomimetic of the invention, in an amount effective so as to
prevent, inhibit or reverse myocardial hypertrophy.
[0098] The invention further provides methods for avoiding
pro-hypertrophic effect of conventional PDE3 inhibition in a
cardiac myocyte. The method comprises contacting the cell with a
peptide, polypeptide or peptidomimetic of the invention, in an
amount to avoid pro-hypertrophic effect of conventional PDE3
inhibition in a cardiac myocyte.
[0099] The invention also provides methods for preventing,
inhibiting or reversing myocardial hypertrophy in a subject. The
method comprises administering to the subject a peptide,
peptidomimetic or small molecule that interacts with a
PDE3-interacting protein that affects myocardial hypertrophy in an
amount effective so as to prevent, inhibit or reverse myocardial
hypertrophy.
[0100] In one embodiment, the invention provides methods for
preventing, inhibiting or reversing myocardial hypertrophy. The
method comprises administering the vector of the invention in a
cardiac myocyte, said vector being genetically modified by
insertion of at least one therapeutic gene into said vector to
produce functional molecules in a sufficient amount to prevent,
inhibit or reverse myocardial hypertrophy in the cell.
[0101] In one embodiment, the invention provides methods for
avoiding pro-hypertrophic effect of conventional PDE3 inhibition in
a subject. The method comprises administering to the subject a
peptide, polypeptide or peptidomimetic of the invention, in an
amount to avoid pro-hypertrophic effect of conventional PDE3
inhibition in the subject.
[0102] In another embodiment, the invention provides methods for
avoiding pro-hypertrophic effect of conventional PDE3 inhibition in
a cardiac myocyte. The method comprises administering the vector of
the invention into the cell, said vector being genetically modified
by insertion of at least one therapeutic gene into said vector to
produce functional molecules in a sufficient amount to avoid
pro-hypertrophic effect of conventional PDE3 inhibition in a
cardiac myocyte.
[0103] In one embodiment, the invention provides methods for
preventing, inhibiting or treating a cardiac disease such as heart
failure, advanced heart failure, NYHA class 3 or 4 symptoms,
hypertension, coronary artery disease, cardiomyopathy, pulmonary
hypertension, cardiac hypertrophy, hypotension, shock, valvular
heart disease, rheumatic heart disease, congenital heart disease,
myocarditis, pericardial disease or arrhythmia. The method
comprises administering to the subject a peptide, peptidomimetic or
small molecule that interacts with a PDE3-interacting protein that
affects cardiac disease in an amount effective so as to prevent,
inhibit or reverse cardiac disease.
[0104] The invention also provides methods for obtaining beneficial
effect of PDE3 inhibition in a subject with reduced or no adverse
effect. The subject may be treated with a PDE3 isoform-specific or
isoform-selective inhibitor.
[0105] Examples of beneficial effect may be increased cardiac
output, augmented myocardial contractility, lower left ventricular
filling pressure, inhibition or reversal of hypertrophic response
of cardiac myocytes to norepinephrine or other G protein-coupled
receptor agonists, increased intracellular Ca.sup.2+ cycling in
cardiac myocytes, increased Ca.sup.2+ uptake from cytosol to
sarcoplasmic reticulum during diastole and increased Ca.sup.2+
release from sarcoplasmic reticulum during systole, decreased
pro-apoptotic signaling, increased intracellular cAMP level in a
cellular compartment associated with increased cardiac output
and/or anti-hypertrophic response, or alteration in phosphorylation
of proteins leading to increased cardiac output and/or
anti-hypertrophic response.
[0106] Examples of adverse effect may be sudden cardiac death,
increased pro-apoptotic signaling, cardiac myocyte hypertrophy and
cardiac hypertrophy.
[0107] In one embodiment, the PDE3 isoform-specific or
isoform-selective inhibitor may be a PDE3A1-specific or
PDE3A1-selective inhibitor. In another embodiment, the
PDE3A1-specific or PDE3A1-selective inhibitor may be a
catalytically compromised, reduced or inactive PDE3A1 or its
derivative.
[0108] In one embodiment, the subject may be a subject with a
cardiac disease such as heart failure, advanced heart failure, NYHA
class 3 or 4 symptoms, hypertension, coronary artery disease,
cardiomyopathy, pulmonary hypertension, cardiac hypertrophy,
hypotension, shock, valvular heart disease, rheumatic heart
disease, congenital heart disease, myocarditis, pericardial disease
or arrhythmia.
[0109] The invention further provides methods for increasing
selectivity of PDE3 inhibition in a cardiac myocyte. The method
comprises contacting the cardiac myocyte with a peptide,
peptidomimetic or small molecule that interacts with a
PDE3-interacting protein at an interaction site selective for a
PDE3 isoform. Alternatively, the method may comprise contacting,
expressing in or introducing in the cardiac myocyte a catalytically
compromised, reduced or inactive form of a PDE3 isoform or its
derivative, so as to selectively inhibit the PDE3 isoform.
[0110] The invention also provides methods for selectively
inhibiting a PDE3 isoform. The method comprises introduction or
expression of an altered or mutated version of the PDE3 isoform to
be selectively inhibited in a cell. In one embodiment, the altered
or mutated version of the PDE3 isoform has altered protein-protein
interaction or has altered or mutated catalytic activity. In
another embodiment, the altered or mutated catalytic activity may
arise due to reduced binding affinity for its substrate (cAMP (or
3',5'-cAMP or 3',5'-cyclic adenosine monophosphate) and/or cGMP (or
3'5'-cGMP or 3',5'-cyclic guanosine monophosphate)), reduced
hydrolysis of its substrate, and/or increased affinity for its
products (5'-AMP (or 5'-adenosine monophosphate) and/or 5'-GMP (or
5'-guanosine monophosphate)).
[0111] Additionally, the invention provides methods for selectively
altering cAMP level within a cellular compartment. The method
comprises introduction or expression of an altered or mutated
version of a PDE3 isoform associated with the cellular compartment.
The altered or mutated version of the PDE3 isoform has altered
protein-protein interaction or has altered or mutated catalytic
activity.
[0112] In one embodiment, the PDE3 isoform may be PDE3A1, PDE3A2,
PDE3A3 or PDE3B.
[0113] In accordance with the practice of this invention, a subject
may be a mammal such as a human, equine, porcine, bovine, murine,
canine, feline, or primate subject. Other mammals are also included
in this invention.
[0114] The invention also provides methods for eliciting positive
inotropic response in a subject without myocardial hypertrophy or
for eliciting positive inotropic and myocardial anti-hypertrophic
responses in a subject. The method comprises administering to the
subject an agent or any of the agents. The agent may be an agent
that selectively decreases PDE3A1 activity in a cardiac myocyte; a
peptide, a peptidomimetic or small molecule that mimics PDE3A1
amino terminus; a peptide, peptidomimetic or small molecule that
interacts with a PDE3A1-interacting protein that selectively
affects cAMP level in the intracellular compartment associated with
PDE3A1 so as to increase Ca.sup.2+ uptake from cytosol to
sarcoplasmic reticulum during diastole and increase Ca.sup.2+
release from sarcoplasmic reticulum during systole; a gene therapy
vector for the delivery and/or expression of a catalytically
compromised, reduced or inactive PDE3A1 mutant gene so as to
selectively increase cAMP locally in an intracellular compartment
associated with endogenous PDE3A1 protein.
[0115] The modes of administration encompassed by the methods of
the invention include but are not limited to gene therapy,
intravenous, intramuscular, intraperitoneal, oral, inhalation and
subcutaneous methods, as well as implantable pump, continuous
infusion, liposomes, suppositories, topical contact, vesicles,
capsules, biodegradable polymers, hydrogels, controlled release
patch and injection.
[0116] Isoform-specific inactivation of PDE3A1 activity may be
achieved by targeting the nucleic acid sequence present in PDE3A1
mRNA but absent in PDE3A2 and PDE3A3 mRNAs. Such sequences can be
used to prepare anti-sense or RNAi molecules to downregulate PDE3A1
expression without affecting the expression of PDE3A2 or PDE3A3.
Alternatively, the 5' region of the PDE3A gene unique to PDE3A1 may
be "knocked out" using procedures known to those skilled in the art
of transgenic animal preparation, so as to preferentially decrease
PDE3A1 activity without affecting or significantly affecting the
activity of the other PDE3A isoforms. Transgenic animals or cell
lines with knocked out PDE3A1 gene (without knocking out PDE3A2 or
PDE3A3 expression), anti-sense PDE3A1 gene, or siRNA targeting
PDE3A1 isoform transgene may be prepared.
[0117] Transgenic non-human mammals or genetically modified
mammalian cells may be prepared that express sequences derived from
the amino-terminal sequence of PDE3A1 protein either as a truncated
protein or as a fusion protein using standing recombinant DNA
methods and molecular biology techniques. Expression of sequences
from the amino-terminal half of PDE3A1 protein in cardiac cells
should protect these cells from hypertrophic inducing agents, such
as norepinephrine and non-isoform-selective PDE3A inhibitors.
[0118] Once generated, the PDE3A1 homologue-deficient animal or
cell line or PDE3A1 amino-terminal polypeptide expressing animal or
cell line can be used to (1) identify biological and pathological
processes mediated by the PDE3A1 protein, (2) identify proteins and
other genes that interact with the PDE3A1 proteins, (3) identify
agents that can be exogenously supplied to overcome a PDE3A1
protein deficiency, (4) serve as an appropriate screen for
identifying mutations within the PDE3A1 gene that increase or
decrease activity, (5) serve as a screen for agents that modulate
cardiac hypertrophy.
[0119] The invention further provides methods for identifying an
agent of interest that mimics a site of interaction of PDE3A1
protein with SERCA2 protein. In one embodiment, the method
comprises (a) contacting the agent with a PDE3A1-SERCA2 complex,
wherein the PDE3A1 protein of the complex comprises phosphoryl
ated-serine-292, phosphorylated-serine-293 and/or phosphorylated
serine-294, or alternatively, singly, doubly or triply mutated
serine-292, serine-293 and/or serine-294 to aspartic acid or to
glutamic acid; (b) determining whether the agent competes with
PDE3A1 of the PDE3A1-SERCA2 complex of (a) for SERCA2 protein
wherein the agent that forms an agent-SERCA2 complex displacing
PDE3A1 from PDE3A1-SERCA2 complex of (a) is the agent of interest
that mimics a site of interaction of PDE3A1 protein with SERCA2
protein thereby identifying the agent of interest that mimics a
site of interaction of PDE3A1 protein with SERCA2 protein.
[0120] The invention additionally provides methods for identifying
an agent of interest that mimics a site of interaction of SERCA2
protein with PDE3A1 protein. In an embodiment of the invention, the
method comprises (a) contacting the agent with a PDE3A1-SERCA2
complex, wherein the PDE3A1 protein of the complex comprises
phosphorylated-serine-292, phosphorylated-serine-293 and/or
phosphorylated serine-294, or alternatively, singly, doubly or
triply mutated serine-292, serine-293 and/or serine-294 to aspartic
acid or to glutamic acid; (b) determining whether the agent
competes with SERCA2 of the PDE3A1-SERCA2 complex of (a) for PDE3A1
protein wherein the agent that forms an agent-PDE3A1 complex
displacing SERCA2 from the PDE3A1-SERCA2 complex of (a) is the
agent of interest that mimics a site of interaction of SERCA2
protein with PDE3A1 protein thereby identifying the agent of
interest that mimics the site of interaction of SERCA2 protein with
PDE3A1 protein.
[0121] In accordance with the practice of the invention, the agent
of interest, SERCA2 protein or PDE3A1 protein may be labeled with a
detectable marker. Examples of suitable detectable markers include,
but are not limited to, a radioactive label, a colorimetric marker,
a fluorophore, an antigen, an epitope or a product of an enzymatic
reaction.
[0122] Methods for identifying an agent of interest that disrupts
the interaction of PDE3A1 protein with SERCA2 protein are also
provided. In one embodiment, the method comprises (a) contacting a
labeled PDE3A1 protein or fragment thereof comprising singly,
doubly or triply phosphorylated serine-292, serine-293 and/or
serine-294, or alternatively, singly or doubly or triply mutated
serine-292, serine-293 and/or serine-294 to aspartic acid or to
glutamic acid with SERCA2 protein, so as to permit formation of a
PDE3A1-SERCA2 complex; (b) contacting the PDE3A1-SERCA2 complex of
(a) with one or more agents of interest that may compete with the
interaction of PDE3A1 or fragment thereof and SERCA2 protein; (c)
detecting the labeled PDE3A1 protein in the PDE3A1-SERCA2 complex
of (b) or the labeled PDE3A1 protein released from the
PDE3A1-SERCA2 complex of (b); (d) determining the amount (i) of
labeled PDE3A1 protein or fragment thereof remaining or released
from the PDE3A1-SERCA2 complex of (c) and comparing that amount (i)
with an amount (ii) from an agent that does not compete with
PDE3A1-SERCA2 complex formation, the amount (i) being less label
bound to the SERCA2 protein or more label free from the SERCA2
protein being indicative that the agent of interest competes with
the complex formation of PDE3A1 protein and SERCA2 protein thereby
identifying the agent of interest that disrupts the interaction of
PDE3A1 protein with SERCA2 protein and/or SERCA2 complex.
[0123] Additionally, methods for identifying an agent of interest
that inhibits the interaction of a PDE3A1 protein with a SERCA2
protein are provided. In one embodiment, the method comprises (a)
contacting one or more agents of interest with the SERCA2 protein
so as to obtain an agent of interest-SERCA2 complex; (b) contacting
the complex of (a) with a labeled PDE3A1 protein or fragment
thereof comprising singly or doubly phosphorylated serine-292,
serine-293, or alternatively, singly or doubly mutated serine-292,
serine-293 to aspartic acid so as to form a PDE3A1-SERCA2 complex;
(c) detecting the label of PDE3A1 protein or fragment thereof so
complexed with the SERCA2 protein of (b) or free from the SERCA2
protein of (b); and (d) quantitatively determining the amount (i)
of labeled PDE3A1 protein or fragment thereof remaining or released
from the PDE3A1-SERCA2 complex of (c), and comparing that amount
(i) with an amount (ii) from an agent that does not compete with
PDE3A1-SERCA2 complex formation, the amount (i) being less label
bound to the SERCA2 protein or more label free from the SERCA2
protein being indicative that the agent of interest competes with
the complex formation of PDE3A1 protein and SERCA2 protein thereby
identifying the agent of interest that inhibits the interaction of
a PDE3A1 protein with a SERCA2 protein.
[0124] In another embodiment, the method comprises (a) contacting
one or more agents of interest with a labeled SERCA2 protein so as
to obtain an agent of interest-SERCA2 complex; (b) contacting the
complex of (a) with a PDE3A1 protein or fragment thereof comprising
singly, doubly or triply phosphorylated serine-292, serine-293
and/or serine-294, or alternatively, singly, doubly or triply
mutated serine-292, serine-293 and/or serine-294 to aspartic acid
or to glutamic acid; (c) detecting the label of SERCA2 protein
bound to the PDE3A1 protein or fragment thereof of (b) or free from
the PDE3A1 protein or fragment thereof of (b); and (d)
quantitatively determining the amount (i) of labeled SERCA2 protein
bound or free from the PDE3A1 protein or fragment thereof of (c),
and comparing that amount (i) with an amount (ii) from an agent
that does not compete with PDE3A1-SERCA2 complex formation, the
amount (i) being less label bound to the SERCA2 protein or more
label free from the SERCA2 protein being indicative that the agent
of interest competes with the complex formation of PDE3A1 protein
and SERCA2 protein thereby identifying the agent of interest that
inhibits the interaction of PDE3A1 protein with SERCA2 protein.
[0125] In yet another embodiment, the method comprises (a)
contacting one or more agents of interest with PDE3A1 protein or
fragment thereof so as to obtain an agent of interest-PDE3A1 or
fragment thereof complex, wherein PDE3A1 or fragment thereof
comprises a singly, doubly or triply phosphorylated serine-292,
serine-293 and/or serine-294, or alternatively, singly, doubly or
triply mutated serine-292, serine-293 and/or serine-294 to aspartic
acid or to glutamic acid; (b) contacting the complex of (a) with a
labeled SERCA2 protein; (c) detecting the label of the SERCA2
protein bound to the pde3a1 protein or fragment thereof or free
from the PDE3A1 protein or fragment thereof; and (d) quantitatively
determining the amount (i) of labeled SERCA2 protein bound or free
from the PDE3A1 protein or fragment thereof, and comparing that
amount (i) with an amount (ii) from an agent that does not compete
with PDE3A1-SERCA2 complex formation, the amount (i) being less
label bound to the SERCA2 protein or more label free from the
SERCA2 protein being indicative that the agent of interest competes
with the complex formation of PDE3A1 protein and SERCA2 protein
thereby identifying the agent of interest that inhibits the
interaction of PDE3A1 protein with SERCA2 protein.
[0126] Further provided are methods for identifying an agent of
interest that competes with the interaction of a PDE3A1 protein and
a SERCA2 protein. In one embodiment, the method comprises: (a)
contacting (i) an agent of interest, (ii) SERCA2 protein, and (iii)
a labeled PDE3A1 protein or fragment thereof comprising singly or
doubly phosphorylated serine-292, serine-293 and/or serine-294, or
alternatively, singly or doubly mutated serine-292, serine-293
and/or serine-294 to aspartic acid or to glutamic acid; (b)
detecting the label of PDE3A1 protein or fragment thereof so
complexed with the SERCA2 protein or free from the SERCA2 protein;
and (c) quantitatively determining the amount (i) of labeled PDE3A1
protein or fragment thereof bound or free from the SERCA2 protein,
and comparing that amount (i) with an amount (ii) from an agent
that does not compete with PDE3A1-SERCA2 complex formation, the
amount (i) being less label bound to the SERCA2 protein or more
label free from the SERCA2 protein being indicative that the agent
of interest competes with the complex formation of PDE3A1 protein
and SERCA2 protein thereby identifying the agent of interest that
competes with the interaction of PDE3A1 protein and SERCA2 protein
and/or SERCA2 complex.
[0127] In another embodiment, the method comprises (a) contacting
(i) an agent of interest, (ii) a labeled SERCA2, and (iii) a PDE3A1
protein or fragment thereof comprising singly, doubly or triply
phosphorylated serine-292, serine-293 and/or serine-294, or
alternatively, singly, doubly or triply mutated serine-292,
serine-293 and/or serine-294 to aspartic acid or to glutamic acid;
(b) detecting the label of SERCA2 protein bound to the PDE3A1
protein or fragment thereof of (a) or free from the PDE3A1 protein
or fragment thereof of (a); and (c) quantitatively determining the
amount (i) labeled SERCA2 protein bound or free from the PDE3A1
protein or fragment thereof and comparing that amount (i) with an
amount (ii) from an agent that does not compete with PDE3A1-SERCA2
complex formation, the amount (i) being less label bound to the
SERCA2 protein or more label free from the SERCA2 protein being
indicative that the agent of interest competes with the complex
formation of PDE3A1 protein and SERCA2 protein thereby identifying
the agent of interest that competes with the interaction of PDE3A1
protein and SERCA2 protein.
[0128] Also provided are methods for identifying an agent of
interest that disrupts the interaction of PDE3A1 protein with
SERCA2 protein. In one embodiment, the method comprises
(a)contacting a PDE3A1 protein or fragment thereof comprising
singly or doubly phosphorylated serine-292, serine-293 and/or
serine-294, or alternatively, singly or doubly mutated serine-292,
serine-293 and/or serine-294 to aspartic acid or to glutamic acid
with a labeled SERCA2 protein, so as to produce a PDE3A1-SERCA2
complex; (b) contacting the PDE3A1-SERCA2 complex of (a) with one
or more agents of interest that may compete with the interaction of
PDE3A1 protein or fragment thereof and SERCA2 protein; (c)
detecting the labeled SERCA2 protein in the PDE3A1-SERCA2 complex
of (b) or the labeled SERCA2 protein released from the
PDE3A1-SERCA2 complex of (b); (d) determining the amount (i) of the
labeled SERCA2 protein remaining or released from the PDE3A1-SERCA2
complex of (c), and comparing that amount (i) with an amount (ii)
from an agent that does not compete with PDE3A1-SERCA2 complex
formation, the amount (i) being less label bound to the SERCA2
protein or more label free from the SERCA2 protein being indicative
that the agent of interest competes with the complex formation of
PDE3A1 protein and SERCA2 protein thereby identifying the agent of
interest that disrupts the interaction of PDE3A1 protein with
SERCA2 protein.
[0129] In accordance with the practice of the invention, the SERCA2
protein may be free or bound to other protein(s) or agent(s). In
accordance with the practice of the invention, the PDE3A1 protein
may be singly, doubly or triply phosphorylated at serine-292,
serine-293, and/or serine-294. In some embodiments, the serine may
be mutated to aspartic acid or glutamic acid.
[0130] Further, in accordance with the practice of the invention,
the label may be a radioactive label, a colorimetric marker, a
fluorophore, an antigen, an epitope or a product of an enzymatic
reaction
[0131] Further still, in accordance with the practice of the
invention, the agent of interest may be a peptide, peptidomimetic
or small molecule.
[0132] Yet further still the PDE3A1 protein or fragment thereof may
be a polypeptide corresponding to amino acid position 146 to 1141
of SEQ ID NO:1 or fragment thereof In another embodiment, the
PDE3A1 protein or fragment thereof is a polypeptide corresponding
to amino acid position 146 to 484 of SEQ ID NO:1. the PDE3A1
protein or fragment thereof comprises an amino acid sequence
corresponding to amino acid position 288 to 297 of SEQ ID NO:1. In
one embodiment of the invention, the PDE3A1 protein or fragment
thereof is a recombinant protein. In yet a further embodiment, the
PDE3A1 protein or fragment thereof is a polypeptide phosphorylated
at amino acid corresponding to serine-292, serine-293 and/or
serine-294 as provided in SEQ ID NO:1. In a further embodiment, the
PDE3A1 protein or fragment thereof is a polypeptide in which amino
acid corresponding to serine-292, serine-293 and/or serine-294 as
provided in SEQ ID NO:1 is/are substituted with aspartic acid.
[0133] In accordance with the practice of the invention, the
screening methods may be performed in a high throughput format. In
another embodiment, the screening method may be performed as a high
content screen.
[0134] Lastly, in screens involving the amino-terminal sequence of
the PDE3A1 protein, such screens may be performed in yeast cells,
including screens (for example two-hybrid screens) to identify
proteins that interact with the amino-terminal half of the PDE3A1
protein, or screens to identify small molecules or macromolecules
(including peptides and peptidomimetics) that compete, interfere,
disrupt or inhibit interaction between the amino-terminal half of
PDE3A1 protein and a known interacting protein.
[0135] The invention provides methods for producing a peptide,
polypeptide or protein of the invention comprising introducing the
host vector system of the invention so as to produce the protein in
the host (e.g., bacteria, baculovirus or yeast cells) and to
recover the protein so produced.
[0136] The peptide or polypeptide of the invention described herein
may be employed in accordance with the present invention by
expression of such peptide or polypeptide of the invention in vivo,
which is often referred to as gene therapy.
[0137] There are two major approaches to getting the nucleic acid
(optionally contained in a vector) into the patient's cells: in
vivo and ex vivo. For in vivo delivery the nucleic acid may be
injected directly into the patient, usually at the sites where the
peptide or polypeptide of the invention is required, i.e., the site
of synthesis of the peptide, polypeptide or peptidomimetic of the
invention, if known (such as, left ventricular region of a heart),
and the site (e.g., wound) where biological activity of the peptide
or polypeptide of the invention is needed. For ex vivo treatment,
the patient's cells may be removed, the nucleic acid is introduced
into these isolated cells, and the modified cells are administered
to the patient either directly or, for example, encapsulated within
porous membranes that are implanted into the patient. There are a
variety of techniques available for introducing nucleic acids into
viable cells. The techniques vary depending upon whether the
nucleic acid is transferred into cultured cells in vitro, or
transferred in vivo in the cells of the intended host. Techniques
suitable for the transfer of nucleic acid into mammalian cells in
vitro include the use of liposomes, electroporation,
microinjection, transduction, cell fusion, DEAE-dextran, the
calcium phosphate precipitation method, etc. Transduction involves
the association of a replication-defective, recombinant viral
(preferably retroviral) particle with a cellular receptor, followed
by introduction of the nucleic acids contained by the particle into
the cell. A commonly used vector for ex vivo delivery of the gene
is a retrovirus, adenovirus or adeno-associated virus (AAV).
[0138] The currently preferred in vivo nucleic acid transfer
techniques include transfection with viral or non-viral vectors
(such as adenovirus, lentivirus, Herpes simplex I virus, or
adeno-associated virus (AAV)) and lipid-based systems (useful
lipids for lipid-mediated transfer of the gene are, for example,
DOTMA, DOPE, and DC-Chol). The most preferred vectors for use in
gene therapy are viruses, most preferably adenoviruses, AAV,
lentiviruses, or retroviruses. A viral vector such as a retroviral
vector includes at least one transcriptional promoter/enhancer or
locus-defining element(s), or other elements that control gene
expression by other means such as alternate splicing, nuclear RNA
export, 3' UTR sequence to enhance translation (such as WPRE) or
post-translational modification of messenger. In addition, a viral
vector such as a retroviral vector includes or may include a
nucleic acid molecule that acts as a translation initiation
sequence. Such vector constructs also include a packaging signal,
long terminal repeats (LTRs) or portions thereof, and positive and
negative strand primer binding sites appropriate to the virus used
(if these are not already present in the viral vector). In
addition, such vector may include a signal sequence for secretion
of a polypeptide from a host cell in which it is placed.
Preferably, the signal sequence for this purpose is a mammalian
signal sequence. If secretion is not desired, such signal sequence
is not included in the sequences used for the translation of the
desired recombinant protein. Optionally, the vector construct may
also include a signal that directs polyadenylation, as well as one
or more restriction sites and a translation termination sequence.
By way of example, such vectors will typically include a 5' LTR, a
tRNA binding site, a packaging signal, an origin of second-strand
DNA synthesis, and a 3' LTR or a portion thereof. Other vehicles
can be used that are non-viral, such as cationic lipids,
polylysine, and dendrimers.
[0139] Kits
[0140] According to another aspect of the invention, kits are
provided. Kits according to the invention include package(s)
comprising compositions of the invention.
[0141] The phrase "package" means any vessel containing compounds
or compositions presented herein. In preferred embodiments, the
package can be a box or wrapping. Packaging materials for use in
packaging pharmaceutical products are well known to those of skill
in the art. Examples of pharmaceutical packaging materials include,
but are not limited to, blister packs, bottles, tubes, inhalers,
pumps, bags, vials, containers, syringes, bottles, and any
packaging material suitable for a selected formulation and intended
mode of administration and treatment.
[0142] The kit can also contain items that are not contained within
the package but are attached to the outside of the package, for
example, pipettes.
[0143] Kits may optionally contain instructions for administering
compositions of the present invention to a subject having a
condition in need of treatment. Kits may also comprise instructions
for approved uses of compounds herein by regulatory agencies, such
as the United States Food and Drug Administration. Kits may
optionally contain labeling or product inserts for the present
compounds. The package(s) and/or any product insert(s) may
themselves be approved by regulatory agencies. The kits can include
compositions in the solid phase or in a liquid phase (such as
buffers provided) in a package. The kits also can include buffers
for preparing solutions for conducting the methods, and pipettes
for transferring liquids from one container to another.
[0144] The kit may optionally also contain one or more other
compositions for use in combination therapies as described herein.
In certain embodiments, the package(s) is a container for
intravenous administration. In still other embodiments compositions
are provided in a polymeric matrix or in the form of a
liposome.
[0145] The following examples are intended to illustrate the
present invention, not to limit the scope of the invention in any
way.
EXAMPLES
Example 1
[0146] Selective targeting of PDE3A1 blocks hypertrophic responses
to isoproterenol
[0147] In neonatal rat ventricular myocytes, conventional PDE3
inhibition promotes cellular hypertrophy, which may be associated
with adverse consequences in heart failure. We questioned what
effect PDE3A1-selective inhibition would have. Faced with the
absence of any known agent that selectively inhibits the catalytic
activity of PDE3A1, we generated an RFP-tagged PDE3A1 construct
with an F1004A substitution in the C-terminus that yields a
catalytically inactive protein. The F1004A substitution is a change
in the amino acid sequence of PDE3A1 at amino acid position 1004
from a phenylalanine to an alanine. We transfected neonatal rat
ventricular myocytes with this dominant-negative construct to
competitively block the protein-protein interactions that localize
PDE3A1 to specific intracellular microdomains. In contrast to
conventional PDE3 inhibition (e.g., cilostamide treatment in FIG.
5), expression of PDE3A1-F1004A (also called "PDE3A1-DN") did not
induce cellular hypertrophy, and most surprisingly expression of
PDE3A1-F1004A in fact blocked the hypertrophic response to
norepinephrine (FIG. 5). This anti-hypertrophic effect was not seen
when cells were transfected with PDE3A2-F1004A dominant negative
mutant (also called "PDE3A2-DN"), a catalytically inactive mutant
of PDE3A2 isoform with a change in the amino acid sequence of
PDE3A2 at amino acid 1004 from a phenylalanine to an alanine (FIG.
5).These findings suggest that while nonselective PDE3 inhibition
raises intracellular cAMP in a manner that promotes hypertrophic
responses, PDE3A1 regulates a compartmentalized pool of cAMP that
is not involved in these responses and actually attenuates them. To
our knowledge, this is the first direct evidence that conventional
PDE3 inhibition and isoform-selective targeting have different
effects in cardiac myocytes, and that some of the adverse
consequences of nonselective PDE3 inhibition may be averted by
isoform-selective targeting involving protein-protein
interactions.
[0148] The distinctions between PDE3 isoforms identified in our
studies with respect to intracellular localization, regulation and
protein-protein interactions suggest that they are likely to have
unique roles in cAMP-mediated signaling in cardiac myocytes.
PDE3A1, being localized to the sarcoplasmic reticulum, may
preferentially regulate the phosphorylation of a limited,
membrane-associated subset of the PDE3A phosphoproteome involved in
intracellular Ca.sup.2+ cycling, with less of a role in regulating
the phosphorylation of cytosolic or mitochondrial proteins that may
contribute to pro-apoptotic and other unwanted responses. Our
observation that a dominant-negative PDE3A1 construct has
anti-hypertrophic effects in neonatal myocytes, in contrast to the
pro-hypertrophic effects of nonselective catalytic-site inhibition
or pro-hypertrophic effects of expressing a dominant negative
PDE3A2 construct, is further reason to suspect that selective
targeting of the PDE3A1 isoform may avoid the adverse consequences
of existing PDE3 inhibitors..sup.42'.sup.43
Example 2
[0149] Introduction
[0150] A major limitation in the treatment of heart failure has
been the failure of existing inotropic agents to improve survival.
Inhibitors of PDE3, a cyclic nucleotide phosphodiesterase expressed
in cardiac myocytes, augment contractility by raising intracellular
cAMP content and increasing the phosphorylation of sarcoplasmic
reticulum proteins involved in Ca.sup.2+ cycling. Their long-term
use, however, leads to an increase in mortality that is likely to
result from their pro-apoptotic and pro-hypertrophic actions.
Finding a way to obtain the benefits of PDE3 inhibition without
these adverse consequences would constitute a major therapeutic
advance.
[0151] Discovery, Target or Product
[0152] Several isoforms of PDE3, localized by protein-protein
interactions to specific intracellular signaling domains, are
expressed in human heart. While conventional PDE3 inhibitors, which
have no selectivity for individual isoforms, promote cardiac
myocyte hypertrophy, we recently discovered that selective
targeting of the sarcoplasmic reticulum-associated isoform PDE3A1
by transfection with a catalytically inactive dominant-negative
(`DN`) construct has pronounced anti-hypertrophic effects. These
effects are not seen when cardiac myocytes are transfected with a
catalytically inactive form of PDE3A2, which is distributed
diffusely within the cells. These findings suggest that an agent
capable of selectively targeting PDE3A1--through its unique
protein-interacting domains rather than its conserved catalytic
site--may lead to a highly localized increase in sarcoplasmic
reticulum-associated cAMP content, producing the inotropic benefits
of PDE3 inhibition without the accompanying adverse effects.
REFERENCES
[0153] 1. Francis S H, Blount M A, Corbin J D. Mammalian cyclic
nucleotide phosphodiesterases: Molecular mechanisms and
physiological functions. Physiological reviews. 2011; 91:651-690
[0154] 2. Taira M, Hockman S C, Calvo J C, Belfrage P, Manganiello
V C. Molecular cloning of the rat adipocyte hormone-sensitive
cyclic gmp-inhibited cyclic nucleotide phosphodiesterase. J Biol
Chem. 1993; 268:18573-18579 [0155] 3. Meacci E, Taira M, Moos M,
Jr., Smith C J, Movsesian M A, Degerman E, Belfrage P, Manganiello
V. Molecular cloning and expression of human myocardial
cgmp-inhibited camp phosphodiesterase. Proceedings of the National
Academy of Sciences of the United States of America. 1992;
89:3721-3725 [0156] 4. Simmerman H K, Jones L R. Phospholamban:
Protein structure, mechanism of action, and role in cardiac
function. Physiol Rev. 1998; 78:921-947 [0157] 5. Takasago T,
Imagawa T, Shigekawa M. Phosphorylation of the cardiac ryanodine
receptor by camp-dependent protein kinase. J Biochem (Tokyo). 1989;
106:872-877 [0158] 6. Beca S, Ahmad F, Shen W, Liu J, Makary S,
Polidovitch N, Sun J, Hockman S, Chung Y W, Movsesian M, Murphy E,
Manganiello V, Backx P H. Phosphodiesterase type 3a regulates basal
myocardial contractility through interacting with sarcoplasmic
reticulum calcium atpase type 2a signaling complexes in mouse
heart. Circulation research. 2013; 112:289-297 [0159] 7. Bristow M
R, Ginsburg R, Minobe W, Cubicciotti R S, Sageman W S, Lurie K,
Billingham M E, Harrison D C, Stinson E B. Decreased catecholamine
sensitivity and beta-adrenergic-receptor density in failing human
hearts. N Engl J Med. 1982; 307:205-211 [0160] 8. Bristow M R,
Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P,
Menlove R, Shah P, Jamieson S, et al. Beta 1- and beta
2-adrenergic-receptor subpopulations in nonfailing and failing
human ventricular myocardium: Coupling of both receptor subtypes to
muscle contraction and selective beta 1-receptor down-regulation in
heart failure. Circ Res. 1986; 59:297-309 [0161] 9. Ungerer M,
Parruti G, Bohm M, Puzicha M, DeBlasi A, Erdmann E, Lohse M J.
Expression of beta-arrestins and beta-adrenergic receptor kinases
in the failing human heart. Circ Res. 1994; 74:206-213 [0162] 10.
Ungerer M, Bohm M, Elce J S, Erdmann E, Lohse M J. Altered
expression of beta-adrenergic receptor kinase and beta 1-adrenergic
receptors in the failing human heart. Circulation. 1993; 87:454-463
[0163] 11. Neumann J, Schmitz W, Scholz H, von Meyerinck L, Doring
V, Kalmar P. Increase in myocardial gi-proteins in heart failure.
Lancet. 1988; 2:936-937 [0164] 12. Feldman A M, Cates A E, Veazey W
B, Hershberger R E, Bristow M R, Baughman K L, Baumgartner W A, Van
Dop C. Increase of the 40,000-mol wt pertussis toxin substrate (g
protein) in the failing human heart. J Clin Invest. 1988;
82:189-197 [0165] 13. Feldman M D, Copelas L, Gwathmey J K,
Phillips P, Warren S E, Schoen F J, Grossman W, Morgan J P.
Deficient production of cyclic amp: Pharmacologic evidence of an
important cause of contractile dysfunction in patients with
end-stage heart failure. Circulation. 1987; 75:331-339 [0166] 14.
Danielsen W, v der Leyen H, Meyer W, Neumann J, Schmitz W, Scholz
H, Starbatty J, Stein B, Doring V, Kalmar P. Basal and
isoprenaline-stimulated camp content in failing versus nonfailing
human cardiac preparations. Journal of cardiovascular pharmacology.
1989; 14:171-173 [0167] 15. Bohm M, Reiger B, Schwinger R H,
Erdmann E. Camp concentrations, camp dependent protein kinase
activity, and phospholamban in non-failing and failing myocardium.
Cardiovasc Res. 1994;28:1713-1719 [0168] 16. Beuckelmann D J,
Nabauer M, Erdmann E. Intracellular calcium handling in isolated
ventricular myocytes from patients with terminal heart failure.
Circulation. 1992; 85:1046-1055 [0169] 17. Baim D S, McDowell A V,
Cherniles J, Monrad E S, Parker J A, Edelson J, Braunwald E,
[0170] Grossman W. Evaluation of a new bipyridine inotropic
agent--milrinone--in patients with severe congestive heart failure.
N Engl J Med. 1983; 309:748-756 [0171] 18. Benotti J R, Grossman W,
Braunwald E, Davolos D D, Alousi A A. Hemodynamic assessment of
amrinone. A new inotropic agent. N Engl J Med. 1978; 299:1373-1377
[0172] 19. Jaski B E, Fifer M A, Wright R F, Braunwald E, Colucci W
S. Positive inotropic and vasodilator actions of milrinone in
patients with severe congestive heart failure. Dose-response
relationships and comparison to nitroprusside. J Clin Invest. 1985;
75:643-649 [0173] 20. Sinoway L S, Maskin C S, Chadwick B, Forman
R, Sonnenblick E H, Le Jemtel T H. Long-term therapy with a new
cardiotonic agent, win 47203: Drug-dependent improvement in cardiac
performance and progression of the underlying disease. J Am Coll
Cardiol. 1983; 2:327-331 [0174] 21. Maskin C S, Sinoway L, Chadwick
B, Sonnenblick E H, Le Jemtel T H. Sustained hemodynamic and
clinical effects of a new cardiotonic agent, win 47203, in patients
with severe congestive heart failure. Circulation. 1983;
67:1065-1070 [0175] 22. Anderson J L. Hemodynamic and clinical
benefits with intravenous milrinone in severe chronic heart
failure: Results of a multicenter study in the united states.
American heart journal. 1991; 121:1956-1964 [0176] 23. Monrad E S,
McKay R G, Baim D S, Colucci W S, Fifer M A, Heller G V, Royal H D,
Grossman W. Improvement in indexes of diastolic performance in
patients with congestive heart failure treated with milrinone.
Circulation. 1984; 70:1030-1037 [0177] 24. Amsallem E, Kasparian C,
Haddour G, Boissel J P, Nony P. Phosphodiesterase iii inhibitors
for heart failure. Cochrane database of systematic reviews
(Online). 2005:CD002230 [0178] 25. del Monte F, Lebeche D, Guerrero
J L, Tsuji T, Doye A A, Gwathmey J K, Hajjar R J. Abrogation of
ventricular arrhythmias in a model of ischemia and reperfusion by
targeting myocardial calcium cycling. Proceedings of the National
Academy of Sciences of the United States of America. 2004;
101:5622-5627 [0179] 26. Lyon A R, Bannister M L, Collins T, Pearce
E, Sepehripour A H, Dubb S S, Garcia E, O'Gara P, Liang L,
Kohlbrenner E, Hajjar R J, Peters N S, Poole-Wilson P A, Macleod K
T, Harding S E. SERCA2a gene transfer decreases sarcoplasmic
reticulum calcium leak and reduces ventricular arrhythmias in a
model of chronic heart failure. Circulation. Arrhythmia and
electrophysiology. 2011; 4:362-372 [0180] 27. Dorn G W, 2nd.
Apoptotic and non-apoptotic programmed cardiomyocyte death in
ventricular remodelling. Cardiovasc Res. 2009; 81:465-473 [0181]
28. Ding B, Abe J, Wei H, Xu H, Che W, Aizawa T, Liu W, Molina C A,
Sadoshima J, Blaxall B C, Berk B C, Yan C. A positive feedback loop
of phosphodiesterase 3 (pde3) and inducible camp early repressor
(icer) leads to cardiomyocyte apoptosis. Proceedings of the
National Academy of Sciences of the United States of America. 2005;
102:14771-14776 [0182] 29. Ding B, Abe J, Wei H, Huang Q, Walsh R
A, Molina C A, Zhao A, Sadoshima J, Blaxall B C, Berk B C, Yan C.
Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis:
Implication in heart failure. Circulation. 2005; 111:2469-2476
[0183] 30. Oikawa M, Wu M, Lim S, Knight W E, Miller C L, Cai Y, Lu
Y, Blaxall B C, Takeishi Y, Abe J, Yan C. Cyclic nucleotide
phosphodiesterase 3a1 protects the heart against
ischemia-reperfusion injury. Journal of molecular and cellular
cardiology. 2013; 64:11-19 [0184] 31. Schmidt M, Dekker F J,
Maarsingh H. Exchange protein directly activated by camp (epac): A
multidomain camp mediator in the regulation of diverse biological
functions. Pharmacological reviews. 2013; 65:670-709 [0185] 32.
Breckler M, Berthouze M, Laurent A C, Crozatier B, Morel E,
Lezoualc'h F. Rap-linked camp signaling epac proteins:
Compartmentation, functioning and disease implications. Cellular
signalling. 2011; 23:1257-1266 [0186] 33. Oestreich E A, Malik S,
Goonasekera S A, Blaxall B C, Kelley G G, Dirksen R T, Smrcka A V.
Epac and phospholipase cepsilon regulate ca2+ release in the heart
by activation of protein kinase cepsilon and calcium-calmodulin
kinase ii. The Journal of biological chemistry. 2009; 284:1514-1522
[0187] 34. Oestreich E A, Wang H, Malik S, Kaproth-Joslin K A,
Blaxall B C, Kelley G G, Dirksen R T, Smrcka A V. Epac-mediated
activation of phospholipase c(epsilon) plays a critical role in
beta-adrenergic receptor-dependent enhancement of ca2+ mobilization
in cardiac myocytes. The Journal of biological chemistry. 2007;
282:5488-5495 [0188] 35. Pereira L, Metrich M, Fernandez-Velasco M,
Lucas A, Leroy J, Perrier R, Morel E, Fischmeister R, Richard S,
Benitah J P, Lezoualc'h F, Gomez A M. The camp binding protein epac
modulates ca2+ sparks by a ca2+/calmodulin kinase signalling
pathway in rat cardiac myocytes. The Journal of physiology. 2007;
583:685-694 [0189] 36. Cazorla O, Lucas A, Poirier F, Lacampagne A,
Lezoualc'h F. The camp binding protein epac regulates cardiac
myofilament function. Proceedings of the National Academy of
Sciences of the United States of America. 2009; 106:14144-14149
[0190] 37. Morel E, Marcantoni A, Gastineau M, Birkedal R, Rochais
F, Gamier A, Lompre A M, Vandecasteele G, Lezoualc'h F.
Camp-binding protein epac induces cardiomyocyte hypertrophy.
Circulation research. 2005; 97:1296-1304 [0191] 38. Pereira L,
Ruiz-Hurtado G, Morel E, Laurent A C, Metrich M,
Dominguez-Rodriguez A, Lauton-Santos S, Lucas A, Benitah J P, Bers
D M, Lezoualc'h F, Gomez A M. Epac enhances
excitation-transcription coupling in cardiac myocytes. Journal of
molecular and cellular cardiology. 2012; 52:283-291 [0192] 39.
Chruscinski A J, Singh H, Chan S M, Utz P J. Broad-scale
phosphoprotein profiling of beta adrenergic receptor (beta-ar)
signaling reveals novel phosphorylation and dephosphorylation
events. PloS one. 2013; 8:e82164 [0193] 40. Netherton S J, Sutton J
A, Wilson L S, Carter R L, Maurice D H. Both protein kinase a and
exchange protein activated by camp coordinate adhesion of human
vascular endothelial cells. Circulation research. 2007; 101:768-776
[0194] 41. Wilson L S, Baillie G S, Pritchard L M, Umana B, Terrin
A, Zaccolo M, Houslay M D, Maurice D H. A phosphodiesterase
3b-based signaling complex integrates exchange protein activated by
camp 1 and phosphatidylinositol 3-kinase signals in human arterial
endothelial cells. The Journal of biological chemistry. 2011;
286:16285-16296 [0195] 42. Roubille F, Tardif J C. New therapeutic
targets in cardiology: Heart failure and arrhythmia: Hcn channels.
Circulation. 2013; 127:1986-1996 [0196] 43. Hayes J S, Brunton L L,
Mayer S E. Selective activation of particulate camp-dependent
protein kinase by isoproterenol and prostaglandin el. J Biol Chem.
1980; 255:5113-5119 [0197] 44. Buxton I L, Brunton L L.
Compartments of cyclic amp and protein kinase in mammalian
cardiomyocytes. J Biol Chem. 1983; 258:10233-10239 [0198] 45.
Nikolaev V O, Moshkov A, Lyon A R, Miragoli M, Novak P, Paur H,
Lohse M J, Korchev Y E, Harding S E, Gorelik J. Beta2-adrenergic
receptor redistribution in heart failure changes camp
compartmentation. Science. 2010; 327:1653-1657 [0199] 46. Zaccolo
M, Pozzan T. Discrete microdomains with high concentration of camp
in stimulated rat neonatal cardiac myocytes. Science. 2002;
295:1711-1715 [0200] 47. Mongillo M, McSorley T, Evellin S, Sood A,
Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse M J, Pozzan
T, Houslay M D, Zaccolo M. Fluorescence resonance energy
transfer-based analysis of camp dynamics in live neonatal rat
cardiac myocytes reveals distinct functions of compartmentalized
phosphodiesterases. Circulation research. 2004; 95:67-75 [0201] 48.
Rochais F, Abi-Gerges A, Horner K, Lefebvre F, Cooper D M, Conti M,
Fischmeister R, Vandecasteele G. A specific pattern of
phosphodiesterases controls the camp signals generated by different
gs-coupled receptors in adult rat ventricular myocytes. Circ Res.
2006; 98:1081-1088 [0202] 49. Mongillo M, Tocchetti C G, Terrin A,
Lissandron V, Cheung Y F, Dostmann W R, Pozzan T, Kass D A,
Paolocci N, Houslay M D, Zaccolo M. Compartmentalized
phosphodiesterase-2 activity blunts beta-adrenergic cardiac
inotropy via an no/cgmp-dependent pathway. Circ Res. 2006;
98:226-234 [0203] 50. Stangherlin A, Gesellchen F, Zoccarato A,
Terrin A, Fields L A, Berrera M, Surdo N C, Craig M A, Smith G,
Hamilton G, Zaccolo M. Cgmp signals modulate camp levels in a
compartment-specific manner to regulate catecholamine-dependent
signaling in cardiac myocytes. Circulation research. 2011;
108:929-939 [0204] 51. Terrenoire C, Houslay M D, Baillie G S, Kass
R S. The cardiac iks potassium channel macromolecular complex
includes the phosphodiesterase pde4d3. The Journal of biological
chemistry. 2009; 284:9140-9146 [0205] 52. Lehnart S E, Wehrens X H,
Reiken S, Warrier S, Belevych A E, Harvey R D, Richter W, Jin S L,
Conti M, Marks A R. Phosphodiesterase 4d deficiency in the
ryanodine-receptor complex promotes heart failure and arrhythmias.
Cell. 2005; 123:25-35 [0206] 53. Leroy J, Richter W, Mika D, Castro
L R, Abi-Gerges A, Xie M, Scheitrum C, Lefebvre F, Schittl J, Mateo
P, Westenbroek R, Catterall W A, Charpentier F, Conti M,
Fischmeister R, Vandecasteele G. Phosphodiesterase 4b in the
cardiac 1-type ca(2)(+) channel complex regulates ca(2)(+) current
and protects against ventricular arrhythmias in mice. The Journal
of clinical investigation. 2011; 121:2651-2661 [0207] 54. Houslay M
D, Baillie G S, Maurice D H. Camp-specific phosphodiesterase-4
enzymes in the cardiovascular system: A molecular toolbox for
generating compartmentalized camp signaling. Circ Res. 2007;
100:950-966 [0208] 55. Houslay M D. Underpinning compartmentalised
camp signalling through targeted camp breakdown. Trends Biochem
Sci. 2010; 35:91-100 [0209] 56. Wechsler J, Choi Y H, Krall J,
Ahmad F, Manganiello V C, Movsesian M A. Isoforms of cyclic
nucleotide phosphodiesterase pde3a in cardiac myocytes. The Journal
of biological chemistry. 2002; 277:38072-38078 [0210] 57. Kenan Y,
Murata T, Shakur Y, Degerman E, Manganiello V C. Functions of the
n-terminal region of cyclic nucleotide phosphodiesterase 3 (pde 3)
isoforms. The Journal of biological chemistry. 2000;
275:12331-12338 [0211] 58. Shakur Y, Takeda K, Kenan Y, Yu Z X,
Rena G, Brandt D, Houslay M D, Degerman E, Ferrans V J, Manganiello
V C. Membrane localization of cyclic nucleotide phosphodiesterase 3
(pde3). Two n-terminal domains are required for the efficient
targeting to, and association of, pde3 with endoplasmic reticulum.
The Journal of biological chemistry. 2000; 275:38749-38761 [0212]
59. Han S J, Vaccari S, Nedachi T, Andersen C B, Kovacina K S, Roth
R A, Conti M. Protein kinase b/akt phosphorylation of pde3a and its
role in mammalian oocyte maturation. The EMBO journal. 2006;
25:5716-5725 [0213] 60. Pozuelo Rubio M, Campbell D G, Morrice N A,
Mackintosh C. Phosphodiesterase 3a binds to 14-3-3 proteins in
response to pma-induced phosphorylation of ser428. Biochem J. 2005;
392:163-172 [0214] 61. Hunter R W, Mackintosh C, Hers I. Protein
kinase c-mediated phosphorylation and activation of pde3a regulate
camp levels in human platelets. The Journal of biological
chemistry. 2009; 284:12339-12348 [0215] 62. Taira M, Hockman S C,
Calvo J C, Taira M, Belfrage P, Manganiello V C. Molecular cloning
of the rat adipocyte hormone-sensitive cyclic gmp-inhibited cyclic
nucleotide phosphodiesterase. The Journal of biological chemistry.
1993; 268:18573-18579 [0216] 63. Leroy M J, Degerman E, Taira M,
Murata T, Wang L H, Movsesian M A, Meacci E, Manganiello V C.
Characterization of two recombinant pde3 (cgmp-inhibited cyclic
nucleotide phosphodiesterase) isoforms, rcgip1 and hcgip2,
expressed in nih 3006 murine fibroblasts and sf9 insect cells.
Biochemistry. 1996; 35:10194-10202 [0217] 64. Hambleton R, Krall J,
Tikishvili E, Honeggar M, Ahmad F, Manganiello V C, Movsesian M A.
Isoforms of cyclic nucleotide phosphodiesterase pde3 and their
contribution to camp hydrolytic activity in subcellular fractions
of human myocardium. J Biol Chem. 2005; 280:39168-39174 [0218] 65.
Roger V L, Go A S, Lloyd-Jones D M, Adams R J, Berry J D, Brown T
M, Carnethon M R, Dai S, de Simone G, Ford E S, Fox C S, Fullerton
H J, Gillespie C, Greenlund K J, Hailpern S M, Heit J A, Ho P M,
Howard V J, Kissela B M, Kittner S J, Lackland D T, Lichtman J H,
Lisabeth L D, Makuc D M, Marcus G M, Marelli A, Matchar D B,
McDermott M M, Meigs J B, Moy C S, Mozaffarian D, Mussolino M E,
Nichol G, Paynter N P, Rosamond W D, Sorlie P D, Stafford R S,
Turan T N, Turner M B, Wong N D, Wylie-Rosett J. Heart disease and
stroke statistics--2011 update: A report from the american heart
association. Circulation. [0219] 66. Roger V L. Epidemiology of
heart failure. Circulation research. 2013; 113:646-659
Example 3
[0220] Materials and Methods
[0221] Use of human heart samples in these studies was approved by
review committees at NHLBI, NIH, and the University of Utah.
[0222] Material
[0223] [.gamma.-.sup.32P]ATP (3000 Ci/mmol) was obtained from MP
Biomedicals (Solon, Ohio, U.S.A.); SuperSignal.RTM. Westpico and
Westfemto chemiluminescent reagents were from Pierce (Rockford,
Ill., U.S.A.); Anti-prohibitin, CD31, PLB, p-PLB, AKAP-LBC, and
AKAP18 antibodies were from Abcam (Cambridge, Mass.). Antibodies to
caveolin-1, caveolin-3, PP2A, PKARII, PKARI, BiP and GM130 were
purchased from BD Biosciences (San Diego, Calif.); anti-.beta.1-AR,
.beta.2-AR, G.alpha.1, G.alpha.S, adenylate cyclase V/VI, 14-3-3,
PP1, and HSP90 antibodies were from Santa Cruz Biotechnology;
SERCA2 antibody was from Affinity Bioreagents;. .beta.3-AR antibody
was from Chemicon; CX-43 antibody was from Thermoscientific;
Calnexin and phosphor-PKA substrate antibodies were from Cell
Signaling; Desmin and SM-actin antibodies were obtained from Dako.
Flag antibodies were from Sigma-Aldrich. Affinity purified rabbit
polyclonal antibody to human PDE3A (accession no. AAA35912) was
generated against peptide corresponding to amino acids 1127-1141
(GKPRGEEIPTQKPDQ) CT domain (C terminal domain). rPKAc and rSERCA2
were obtained from Calbiochem and Abnova, respectively. Other
materials were obtained as indicated.
[0224] Methods
[0225] Preparation of Subcellular Fractions of Human Myocardium
[0226] Human myocardium was obtained from the left ventricular free
wall of explanted hearts from patients with idiopathic dilated
cardiomyopathy undergoing cardiac transplantation (University of
Utah). Normal human heart samples were also obtained from Capital
Biosciences, Inc (Rockville, Md.). Heart tissues were quickly
washed in ice-cold PBS, chopped with scissors and homogenized (4
ml/g tissue) at 4.degree. C. in buffer A (0.29 M sucrose, 10 mM
MOPS, 2 mM EGTA, Roche protease inhibitor cocktail, pH 7.0) with a
rotor-stator homogenizer (Omni International, Marietta, Georgia,
USA) at 30,000 rpm (60-80 seconds, on ice), followed by
homogenization (on ice, 20 strokes in a glass Dounce homogenizer).
Homogenates were centrifuged (11,000.times.g, 15 min) in a
Beckman
[0227] JA-20 rotor. Supernatants were further centrifuged
(150,000.times.g, 1 h) in a Beckman 55.2 Ti rotor, yielding
cytosolic fractions and pellets. Pellets were resuspended by hand
homogenization (glass-glass) in two volumes (relative to starting
material) of buffer A without EGTA. Following resedimentation
(150,000.times.g, 1 h), the pellet, i.e., `myocardial membrane
fraction`, was suspended in buffer A (without EGTA) using a dounce
homogenizer and stored at -80.degree. C. Each preparation was made
from combined tissues from at least three different hearts. For
some experiments, myocardial membranes were solubilized in buffer B
(50 mM HEPES, 50 mM sucrose, 1 mM EDTA, 10 mM pyrophosphate, 5 mM
NaF, 100 mM NaCl, 5 mM MgCl.sub.2, 0.1 .mu.M okadaic acid, Roche
protease inhibitor cocktail, pH 7.5). Myocardial membranes were
solubilized by homogenization (using a Dounce homogenizer, 20
strokes) and incubation/rotation of homogenates with Nonidet P40
(v/v, 1% final)(Thermoscientific) for 1 h at 4.degree. C.
Solubilized membrane proteins (supernatants) were obtained by
centrifugation [24000 rev/min for 30 min at 4.degree. C., using a
SW41 Ti rotor (Beckman)].
[0228] For isolation of SR vesicles, 11,000.times.g supernatants
were centrifuged (45 min, 43,666.times.g) in a Beckman SW41 rotor,
as described (15). The resultant pellet was resuspended in buffer
containing 0.6 M KCL and 20 mM Tris (pH 6.8) and centrifuged for
(45 min, 43,666.times.g). The final washed pellet containing SR
fractions was suspended in buffer A and stored at -80.degree.
C.
[0229] cAMP PDE Assay
[0230] PDE3 activity, (that portion of total PDE activity inhibited
by 1.0 .mu.M cilostamide, a selective PDE3 inhibitor), was measured
by modification of our published method (16), using 0.1 .mu.M
[.sup.3H] cAMP (35000 cpm) as substrate. PDE activity is expressed
as pmol cAMP hydrolyzed/min/mg.
[0231] Immunoprecipitation and Immunoblotting
[0232] Solubilized myocardial membranes were cleared by incubation
for 1 h at 4.degree. C. with 5 .mu.g nonimmune IgG, and then with
50 .mu.l Protein G-Magnetic beads (Thermoscientific) for 30 min,
before placing the tube into a magnetic stand to collect the beads
against the side of the tube. Cleared fractions were incubated
overnight at 4.degree. C. with specified antibodies or with
non-immune IgG, followed by incubation with fresh
Protein-G-Magnetic beads for 1 h before placing the tube into a
magnetic stand to collect the beads. After washing (3.times.,
Buffer B), Protein-G-Magnetic-beads-bound, immunoprecipitated,
proteins were eluted by boiling in 200 .mu.l Laemmli's SDS buffer,
and samples (15 .mu.l) were subjected to SDS-PAGE,
electro-transferred to nitrocellulose membranes (Invitrogen), and
immunoblotted sequentially with appropriate primary antibodies and
HRP-labeled secondary antibody (Thermoscientific). Immunoreactive
proteins were reacted with Supersignal.RTM. Westpico or Westfemto
chemiluminescent reagents (Thermoscientific); signals were detected
with Image reader LAS3000 (GE Healthcare).
[0233] Effect of cAMP and Recombinant PKA Catalytic Subunit (rPKAc)
on 45Ca.sup.2+ Uptake or SERCA Activity
[0234] SR fractions (50.about.100 .mu.g) were incubated (30 min,
30.degree. C.) without or with 250 units of rPKAc or indicated
concentrations of cAMP in buffer containing 10 mM imidazole-HCl (pH
7.0), 0.1 .mu.M okadaic acid, 10 mM MgCl2, 5 mM DTT, 0.5 mM ATP and
1.times. phosphatase inhibitor cocktail. The reaction mixture was
centrifuged (100,000.times.g, 30 min, 40 C), and the resulting
pellets were resuspended in 0.3 M sucrose, 10 mM K-PIPES buffer
containing 1.times. phosphatase inhibitor cocktail, pH 7.0, for
Ca.sup.2+ uptake and SERCA activity assays.
[0235] Measurement of .sup.45Ca.sup.2+ Uptake in SR Vesicles
[0236] Oxalate-dependent Ca.sup.2+ uptake was quantified as
described previously (17). Briefly, SR vesicles (50 .mu.l, 10-20
.mu.g protein), prepared as described above, were incubated at
37.degree. C. for 0.5-3 min in 0.4 ml Ca.sup.2+ uptake buffer,
consisting of 50 mM imidazole-HCl, pH7.0, 100 mM KCl, 6 mM MgCl2,
10 mM NaN.sub.3 (to inhibit mitochondrial Ca2+ uptake), 10 mM
potassium oxalate; 20 .mu.M ruthenium red (to inhibit SR Ca2+
release); 0.1 mM EGTA; .sup.45CaCl.sub.2 (10,000 dpm/nmol) (Perkin
Elmer, Cat #NEZ013), and unlabeled CaCl.sub.2 (0.1-1 .mu.M free
Ca.sup.2+). Uptake was initiated by adding 50 mM ATP (50 .mu.l) and
terminated at indicated times by filtration through 0.45 .mu.m
Millipore filters. After washing four times with 4 ml buffer
containing 140 mM KCl, 10 mM NaCl, 2 mM MgCl.sub.2, 1 mM CaCl.sub.2
and 50 mM imidazole-HCl, (pH 7.0), radioactivity retained on the
filters was quantified by liquid scintillation counting. Free
[Ca.sup.2+] was calculated using a program obtained at
http://www.stanford.edu/.about.cpatton/webmaxc/webmaxcS.htm.
[0237] SERCA Activity Assay
[0238] Ca.sup.2+-ATPase activity in SR fractions was determined by
measuring the amount of P.sub.i released after addition of ATP,
using the malchite green ATPase method (18). Samples were assayed
in the presence or absence of thapsigargin (10 .mu.M), since SERCA2
activity was determined as that portion of total activity inhibited
by thapsigargin. The assay mixture (total volume, 125 .mu.l)
contained 0.125 M KCl, 20 mM imidazole, pH 7.0, 0.1 mM EGTA, 0.103
mM CaCl.sub.2, 1 .mu.M ionomycin and 10 .mu.g SR. To initiate the
reaction, 25 .mu.l of substrate (Mg.sup.2+-ATP) was added to a
final concentration of 0.25 mM. The mixture was incubated at room
temperature for 0.5-3 min. The reaction was terminated by adding 25
.mu.l of 250 g/L TCA, vortexed quickly, and centrifuged
(8,000.times.g, 3 min). Supernatants (20 .mu.l) were added to 96
well plates, followed by color reagent (100 .mu.l/sample), which
consisted of 54 mM ammonium molybdate and 0.73 mM Malachite green.
After 1 min, Na-citrate (340 g/L, 10 .mu.l) was added, with gentle
shaking (room temperature for more than 20 min), after which plates
were scanned at 650 nm. P.sub.i was calculated by converting OD650
to nanomoles by means of a standard curve.
[0239] cAMP-Dependent Phosphorylation of Endogenous PLB
[0240] Resuspended myocardial membranes (20 .mu.g protein) were
phosphorylated in buffer containing 50 mM HEPES, 5 mM MgCl.sub.2,
50 mM sucrose, 100 mM NaCl, 5 mM NaF, 10 mM PP.sub.i, 1 mM EDTA, pH
7.6. After incubation (2 min, 30.degree. C.) in the absence or
presence of cilostamide (1 .mu.M) or rolipram (10 .mu.M), 0.5 mM
ATP and 0.1 .mu.M cAMP were added as indicated, and incubations (50
.mu.l final volume) were continued for 30 min. Reactions were
terminated by addition of SDS-containing buffer (25 .mu.l). Samples
were immediately boiled (5 min), and subjected to SDS PAGE.
[0241] Phosphorylation of Ser-16 PLB and endogenous PLB, PKAc, and
PDE3A proteins were identified by Western immunoblotting.
[0242] Immunohistochemistry
[0243] Frozen heart blocks were prepared from snap frozen normal
human heart samples obtained from Capital Biosciences, Inc, and
sections were made at a thickness of 10 .mu.m using a microtome at
-25.degree. C. Paraformaldehyde-fixed cryostat heart sections were
washed in PBS (3.times.5 min), blocked and permeabilized in 10%
donkey serum containing 0.05% Triton X-100 (6 h, 4.degree. C.).
Slides were incubated in blocking buffer with primary antibody
overnight and washed with PBS (3.times.5 min) before incubating in
blocking buffer for 2 h with secondary antibody (Alexa Fluor 488 or
Alexa fluor 594; Molecular Probes). PDE3A antibody against human
PDE3A aa1127-1141 (GKPRGEEIPTQKPDQ; CT, C-terminus) was used. As
controls, slides were incubated with nonimmune IgG or with primary
antibodies incubated with blocking (immunizing) peptides, prior to
staining with secondary antibody. For peptide blocking/competition
experiments, approximately 20 .mu.g anti-PDE3A-CT antibody was
combined with 100 .mu.g of blocking peptide in a small volume (500
.mu.l) of PBS and incubated (2 h, room temperature or overnight,
4.degree. C.). After blocking with the immunizing peptides,
antibody/peptide mixtures were diluted into blocking buffer and
used for staining of samples.
[0244] Slides were viewed with a Zeiss LSM510 laser scanning
confocal microscope.
[0245] Gel Filtration Chromatography on Superose 6 Columns
[0246] Solubilized myocardial membranes (1.0 ml, 3 mg total
protein), prepared as described above, were applied to a Superose 6
HR 10/30 column (AKTA FPLC System, GE healthcare) that was
equilibrated and eluted with buffer C (buffer B without sucrose,
containing 150 mM NaCl and 1% NP-40) (FIG. 7). Chromatography of
solubilized myocardial membranes (3 mg) on Superose 6 HR was
repeated 2 times and LMW fractions (#24-34) were pooled and
concentrated via centriprep. The concentrated fractions were split,
and, after treatment without or with rPKAc, were used for
re-chromatography on S6 columns (FIG. 8). For immunoprecipitation
studies, LMW fractions from two similar experiments were also
pooled, concentrated, split, and, after treatment without or with
rPKAc, used to study co-immunoprecipitation of PDE3A with
components of the SERCA2/AKAP18 signalosome (FIG. 9). Cytosolic
fractions (1.0 ml, 3 mg total protein), prepared as described
above, were also applied to Superose 6 which was equilibrated and
eluted with buffer D (buffer C, without NP40) (FIG. 7). Portions of
the fractions (0.5 ml) were used for assay of PDE3 activity or SDS
PAGE/Western blotting (using affinity-purified rabbit anti-PDE3A
and other indicated antibodies). In some experiments, portions of
eluted HMW and LMW peaks from solubilized membrane and cytosol
fractions were pooled, concentrated, and immunoprecipitation was
carried out with anti-PDE3A-CT antibody and Protein-G-Magnetic
beads as described above, followed by immunoblotting with
anti-phospho-PKA-substrate and anti-PDE3A antibodies.
[0247] In Vitro Phosphorylation of PDE3A
[0248] PDE3A immunoprecipitated from solubilized myocardial
membranes (500 .mu.g) was incubated for 1 h at 30 .degree. C. in
the absence or presence of 250 units rPKAc [One unit is defined as
the amount of enzyme required to transfer 1 pmol phosphate to PKA
peptide (GRTGRRNSI) per min at 30.degree. C.] or rPKAc plus 10
.mu.M PKI (PKA inhibitor) in phosphorylation buffer (50 mM HEPES,
pH 7.5, 5 mM MgCl.sub.2, 100 mM NaCl, 1 mM EDTA, 10 mM PP.sub.i, 5
mM NaF, 0.1 .mu.M okadaic acid) without or with 200 .mu.M ATP or
200 .mu.M ATP supplemented with [.gamma..sup.32P] ATP (10 .mu.Ci
per reaction; 3000 Ci/mmol stock). Reaction mixtures were boiled in
sample buffer and subjected to SDS-PAGE. Phosphorylation of PDE3A
was detected by scanning the wet gels on a Phospho Imager (GE
Healthcare). Proteins on wet gels were then electrophoretically
transferred to nitrocellulose membranes, and PDE3A was identified
by Western blotting using anti-PDE3A antibody.
[0249] Co-Immunoprecipitation of PDE3A with Components of SERCA2
Regulatory Signalosomes from Pooled LMW Fractions After Incubation
with or without rPKAc
[0250] Pooled LMW Superose 6 fractions from solubilized myocardial
membranes were prepared as described above and incubated without
(control) or with rPKAc in buffer containing 200 .mu.M ATP for 1 h
at 30.degree. C. At the completion of these reactions, fractions
were cleared, and incubated overnight with nonimmune IgG (10 .mu.g)
or anti-PDE3A-CT antibody (10 .mu.g) before incubation (1 h) with
Protein-G-magnetic beads. Protein-G-Magnetic-beads-bound,
immunoprecipitated proteins were washed, eluted, and samples (15
.mu.l) were immunoblotted with indicated antibodies as described
above. Total membrane protein (10 .mu.g, input) were loaded on gels
as controls.
[0251] Co-Immunoprecipitation of Flag-Tagged Recombinant Human
PDE3A (rhPDE3A) Variants and rSERCA2 After Incubation with or
without rPKAc
[0252] Flag-tagged rhPDE3A1 and its phosphorylation site mutants
[rhPDE3A1-S292A/293A (M1), rhPDE3A1-S312A (M2), rhPDE3A1-S428A
(M3), rhPDE3A1-S438A (M4), rhPDE3A1-S292A/293A/312A/438A (M5) open
reading frame [accession #NP 000912] was synthesized by Genscript,
Inc (Piscataway, N.J.), subcloned into pAcSG2 baculoviral
expression vector. Flag-tagged rhPDE3A variants and phosphorylation
site mutants were expressed in SF21 cells [(10-20).times.106 SF21
cells/75-cm2 flask] as described (19,20). SF21 cells were
harvested, sedimented (10 min, 1000.times.g, 4.degree. C.), washed
twice with ice-cold PBS, resuspended, homogenized (in a Dounce
homogenizer) in buffer B and sonicated vector, and expressed in
SF21 cells (19). A comparison of the translated sequences of human
AKAP18.gamma. (AC NP_057461 and AK300587; 348 aa residues) and rat
AKAP18.delta. (3) (AC QJP77; 352 aa residues) indicate that eight
of the first twelve aa residues of human AKAP18.gamma. and rat
AKAP18.delta. are identical, and that the proteins are homologous
(.about.74% aa identity). SF21 cell extracts, which contained
his-tagged-rAKAP18.delta., were prepared as described above.
Flag-tagged rhPDE3A1 (usually 50 arbitrary (u) units) was incubated
(30 min, 30.degree. C.) with rAKAP18.delta. (200 .mu.l, containing
50 ng of recombinant protein), with or without different
concentrations of rPKAc (final volume, 300 .mu.l) in buffer B
containing 2 mM DTT and 200 .mu.M ATP. Reactions were stopped by
dilution of reaction mixtures to 1.0 ml with buffer B containing 1
mg/ml SF21 cell lysates, and cleared as described above (cf
`Immunoprecipitation and immunoblotting` subsection). His-tagged
rAKAP18.delta. was immunoprecipitated with anti-his Mab Mag-beads
(Genscript). Anti-his Mab Mag beads-bound immunoprecipitates were
washed, collected, and anti-his Mab Mag-beads-bound proteins were
eluted by boiling in Laemmli's SDS buffer (100 .mu.l) and samples
(15 .mu.l) of immunoprecipitated proteins as well as of reaction
mixtures (input proteins') were immunoblotted with indicated
antibodies as described above.
[0253] LC-MS/MS Analysis of PDE3A Immunoprecipitates
[0254] PDE3A immunoprecipitates were separated by 4-20% SDS-PAGE;
proteins were stained with Coomassie SimplyBlue.TM. SafeStain
(Invitrogen, Cat #LC6060) for 1 hour at RT, followed by destaining
(overnight, RT) in pure water. Sequential gel slices were cut out
according to molecular weight. Gel slices were diced into small
cube pieces (1-2 mm.sup.2) and placed in 1.5 ml tubes. Gel pieces
were destained by 25 mM NH4HCO.sub.3/50% acentonitrile (3.times.10
min), and vortexed occasionally. Using gel-loading tips,
supernatants were discarded. Gel pieces were dessicated by speed
vac. After reduction in buffer (10 mM DTT, 25 mM NH.sub.4HCO.sub.3;
56.degree. C., 1 h) and alkylation (55 mM iodoacetamide, 25 mM
NH4HCO.sub.3; 45 min, RT), gel pieces were dessicated by speed vac
and digested with 10 ng/.mu.l trypsin (Promega) (overnight,
37.degree. C.).
[0255] Tryptic peptides were released from the gels upon vortexing
and sonication. Released peptides were purified, concentrated, and
desalted by reversed phase C18 ZipTip (Millipore). Peptide samples
were stocked in 0.1% formic acid (FA) for LC-MS/MS analysis (LTQ
Orbitrap Velos mass spectrometer, Thermofisher Scientific, San
Jose, Calif.) using CID fragmentation. At least two peptides were
obtained for each protein with MS/MS. Proteins were identified from
the acquired spectra with the MASCOT database search function.
[0256] Results
[0257] PDE3A Co-Localizes with PLB, SERCA2 and AKAP18 in the
Z-Bands of Human Cardiac Myocytes
[0258] The intracellular distribution of PDE3A in human cardiac
myocytes was examined by immunostaining with anti-PDE3A-CT
antibodies (FIG. 6). Consistent with our previous studies (21,22),
co-staining with anti-PDE3A and anti-desmin antibodies demonstrated
that PDE3A is distributed in a striated pattern in the Z-lines of
these cells (FIG. 6A, B), with little co-localization with myomesin
(M-line marker protein) (FIG. 6B). PDE3A co-localized with PLB,
SERCA2 and an AKAP18 variant that was detected by antibodies to
human AKAP18 (Abcam: Ab 30987) (FIG. 6A, B).
[0259] PDE3 Inhibition Potentiates cAMP-Dependent Phosphorylation
of PLB and Its Stimulation of Ca.sup.2+ Uptake in Human Myocardial
Membranes
[0260] The effects of PDE3 inhibition on PLB phosphorylation and
Ca.sup.2+ uptake were examined in microsomes prepared from human
left ventricular myocardium. At 0.1 .mu.M cAMP, phosphorylation of
PLB at S16 by endogenous PKA was stimulated by the PDE3-selective
inhibitor cilostamide (FIG. 7A, 7B). Since PDE4 has also been found
to co-immunoprecipitate with PLB in subcellular preparations from
human myocardium (23), we tested the effect of the PDE4-specific
inhibitor rolipram on PLB phosphorylation, and found no effect
(FIG. 7A, 7B). This result corresponds to the lower amount of
rolipram-sensitive cAMP-hydroltyic activity relative to
cilostamide-sensitive cAMP-hydrolytic activity in these
preparations (FIG. 7C). cAMP increased ATP-dependent,
oxalate-supported Ca.sup.2+ uptake (FIG. 7D), and this effect was
potentiated by cilostamide (FIG. 7E). Addition of rPKAc stimulated
both Ca.sup.2+ uptake and SERCA2 activity (FIG. 7F). These results
indicate that PDE3 has a specific role in regulating
phosphorylation of PLB by cAMP/PKA and the consequent stimulation
of Ca.sup.2+ uptake in human myocardium.
[0261] Phosphorylated PDE3A Isoforms Co-Elute with PLB, SERCA2 and
AKAP18 in High-Molecular-Weight Peaks from Solubilized Human
Myocardial Membranes
[0262] In previous studies, we showed that the phosphorylation of
rPDE3A isoforms in transfected HEK293 cells promotes their
interactions with other proteins (14). To address whether
phosphorylation might promote the integration of PDE3A into
multiprotein SERCA2 complexes in cardiac myocytes, we analyzed
cytosolic and NP40-solubilized membrane proteins from human left
ventricular myocardium by Superose (S6) gel-filtration
chromatography (FIG. 8). As seen in FIG. 8A, PDE3 activity in
solubilized myocardial membrane proteins was recovered in distinct
HMW (.about.3000 kD) and LMW (.about.700 kD) peaks. Western
blotting with anti-PDE3A antibodies indicated that the HMW and LMW
peaks contained all three PDE3A isoforms. In contrast, upon S6
chromatography of cytosolic fractions, from which PDE3A1 is absent,
PDE3A2 and PDE3A3 eluted in a single LMW peak (FIG. 8B). As seen in
FIG. 8C, immunoprecipitation of PDE3A from pooled HMW or LMW peaks
of solubilized membranes, followed by Western blotting with
anti-phosphorylated PKA substrate antibodies, demonstrated that
PDE3A1 was highly and selectively phosphorylated at PKA sites in
HMW peaks. These results suggested that phosphorylation of
endogenous PDE3A1 by PKA may be involved in its incorporation into
HMW macromolecular complexes.
[0263] To confirm these findings, studies of phosphorylation of
PDE3A by rPKAc were carried out in vitro using immunoprecipitated
PDE3A from solubilized myocardial membranes. PDE3A was incubated
with .gamma..sup.32P-ATP in the presence or absence of rPKAc.
Phosphorimaging of wet gels after SDS-PAGE and Western blotting
demonstrated that both PDE3A1 and PDE3A2 could be markedly
phosphorylated by rPKAc (FIG. 8D, upper panels), with little if any
increase in the phosphorylation of PDE3A3 under these conditions.
As seen in FIG. 8D (lower panel), phosphorylation by rPKAc was
accompanied by a stimulation of PDE3A activity (35% compared to
controls, p<0.01).
[0264] PDE3A Associates Phosphorylation-Dependently with PLB,
SERCA2 and AKAP18
[0265] We examined the effects of phosphorylation by PKA on the
interaction of PDE3A1 with PLB, SERCA2 and AKAP18 (FIGS. 9 and 10).
Pooled and concentrated membrane LMW S6 fractions from two
different experiments (analogous to fractions 24-34 in FIG. 8A)
were divided and incubated in the absence or presence of rPKAc, and
then re-chromatographed on S6-columns (FIG. 9) or
immunoprecipitated with anti-PDE3A antibody (FIG. 10). PDE3
activity in control pooled membrane S6-column LMW fractions
exhibited an apparent molecular mass of 700 kDa during
re-chromatography on S6-columns (FIG. 9); after incubation with
rPKAc, however, the apparent molecular mass of most of the eluted
and PDE3A1 and PDE3A2 was .gtoreq.3000 kDa, while most of the
PDE3A3, which was not phosphorylated or only weakly phosphorylated
by rPKAc (FIG. 8), remained in the low-MW fraction (FIG. 9). This
indicates that phosphorylation by rPKAc (cf FIG. 8D) induced the
shift in elution of PDE3A1 and PDE3A2. Shifts from LMW to the BMW
fractions were also observed for AKAP18, PLB, PKA-RII and PKA
catalytic subunits as well as PP1 and Cav3. As seen in FIG. 10,
incubation of pooled membrane LMW fractions with rPKAc increased
the co-immunoprecipitation of PDE3A with AKAP18 (not AKAP LBC),
SERCA2, PP2A, PP1 and cav3, but reduced the co-immunoprecipitation
of PLB. These results suggest that phosphorylation of
membrane-associated PDE3A promotes its integration into
macromolecular complexes containing AKAP18, SERCA2 and other
proteins involved in the cAMP-mediated regulation of Ca.sup.2+
transients and myocardial contractility. The decreased association
of PLB with these proteins following phosphorylation by PKA is
consistent with the integration of PLB into this complex being
dependent upon its interactions with SERCA2 and AKPA18, both of
which are reduced by its phosphorylation by PKA at S16 (2,24).
[0266] Because PDE3A1 is the most highly PKA-phosphorylated isoform
in human myocardium (FIG. 8), we studied its
phosphorylation-dependent interactions with SERCA2 and
AKAP18.delta. in more detail using recombinant forms of these
proteins. The co-IP of both proteins with PDE3A1 was increased by
phosphorylation of PDE3A1 by rPKAc (FIG. 11, FIG. 12)
[0267] To gain insight into molecular mechanisms contributing to
the phosphorylation-dependent interaction of PDE3A1 and SERCA2, we
generated PDE3A1 constructs with C- and N-terminal deletions and
serine-to-alanine mutations at PKA sites in the PDE3A1 N-terminus.
rSERCA2 also co-immunoprecipitated with rPDE3A-RD, a construct
containing only the N-terminal portion of
[0268] PDE3A1 (aa 146-484, including both its shared sequence with
PDE3A2 and its unique N-terminal extension), but not with
rhPDE3A-.DELTA.510, a recombinant form from which the first 510 aa
of the PDE3A open reading frame were deleted (FIG. 11). This
indicated that interactions with SERCA2 involved the N-terminus of
PDE3A1.
[0269] With at least four PKA consensus sites (R--R--X--S/T) in the
rhPDE3A1 N-terminus, we inserted serine-to-alanine mutations in
these sites: S292/293A (M1), S312A (M2), S428A (M3), S438A (M4),
S292/S293/S312/S438 (M5). The M1 and M5 mutations markedly
diminished PKA-stimulated interactions with SERCA2. PDE3A mutants
M2 (S312A) and M3 (S428A) showed slightly decreased
phosphorylation-dependent interactions with SERCA2, while the PDE3A
M4 mutation (S438A) had no effect (FIG. 11). These data indicate
that S292/S293 is the major PKA site regulating the interaction of
PDE3A1 with SERCA2.
[0270] Discussion
[0271] PDEs have critical roles in the compartmentation of cAMP
signaling (25-28). A number of studies involving many different
PDEs have demonstrated that these enzymes are recruited to specific
intracellular complexes through protein-protein interactions, and
that, as a result of this localization, individual PDEs are able to
regulate specific cAMP-mediated signaling pathways with great
precision. Understanding the mechanisms by which PDEs are localized
to multiprotein complexes and the consequences of this localization
are especially important in cardiac muscle, where inhibitors of the
PDE3 family of enzymes are used to increase contractility in
patients with heart failure. In earlier work, we showed that
inotropic responses to PDE3 inhibition in mice, which correlated
with increases in intracellular Ca2+ transients, are attributable
specifically to isoforms in the PDE3A subfamily, and that PDE3A1 is
a component of a SERCA2-regulatory signalosome (1,2,22). In the
experiments described here, we have confirmed that PDE3A1 is part
of a similar SERCA2-, PLB- and AKAP18-containing complex localized
to sarcomeric Z-bands in human cardiac myocytes. Our observation
that PDE3-selective inhibition (but not PDE4 inhibition) increases
the phosphorylation of PLB by endogenous PKA and stimulates Ca2+
uptake in SR-enriched vesicles prepared from this tissue is
evidence for the physiologic and therapeutic importance of this
association. Finally, we showed that the interactions of PDE3A1
with SERCA2 and AKAP18 are phosphorylation-dependent, and that the
former interaction is mediated principally by the phosphorylation
of PDE3A1 at S292/S293, a sequence in its unique N-terminal
extension.
[0272] While both PDE3 and PDE4 have been found to co-IP with PLB
in complexes from mouse and human myocardium(22,23,29), our studies
show that PDE4-selective inhibition does not potentiate the
PKA-mediated stimulation of PLB phosphorylation and SERCA2
activity, while PDE3-selective inhibition does. This most likely
reflects the higher amount of PDE3 activity relative to PDE4
activity in SR preparations from human myocardium.
[0273] Previous studies of PDE3B showed a role for N-terminal
phosphorylation in integrating the enzyme into multiprotein
complexes in response to insulin or .beta.3-adrenergic receptor
agonists. N-terminal phosphorylation in response to PKA and PKC
activation has also been shown to regulate the interactions of
PDE3A isoforms with 14-3-3 and with other (as-yet-unidentified)
proteins (14). The interactions with 14-3-3 were consequences of
the phosphorylation of two sites in the N-terminal sequence common
to both PDE3A1 and PDE3A2, S312 and S428; there was no evidence for
the involvement of any other phosphorylation sites in regulating
protein-protein interactions. Our new results showing that PDE3A
interacts directly with both SERCA2 and AKAP18 in a
phosphorylation-dependent manner, and that, in the case of SERCA2,
this interaction is mediated by the phosphorylation of S292/S293, a
site unique to PDE3A1 that was not known to have a role in
regulating protein-protein interactions, add significantly to our
understanding of the molecular mechanisms through which PDE3 is
localized to intracellular signaling complexes that control
intracellular Ca.sup.2+ handling.
[0274] As noted earlier, the sequences of PDE3A1 and PDE3A2 are
identical save for the presence in the former of a unique
154-amino-acid N-terminal extension. Understanding how this
extension affects the function of PDE3A1 is therefore central to
understanding the unique roles of the two isoforms. A growing body
of evidence indicates that several molecular mechanisms are
involved. The hydrophobic loops within this sequence restrict
PDE3A1's distribution to cellular and intracellular membranes.
Within these membranes, the protein-protein interactions of each
isoform are clearly different: the 5-HT receptor, for example,
binds to PDE3A1 but not to PDE3A2 (30). The N-terminal extension
also affects the tertiary structure of the downstream sequence: its
presence converts S428 from being a strong PKC site in PDE3A2 to a
weaker one in PDE3A1. This contributes to the selective regulation
of these isoforms by preferential phosphorylation of PDE3A1 at the
protein-binding site S312 by PKA and preferential phosphorylation
of PDE3A2 by PKC at the protein-binding site S428 (14). Since
phosphorylation promotes the association of each isoform with
different proteins, this is likely to be a factor in the two
isoforms having distinct interactomes. In addition, phosphorylation
by PKB of the S292/S293 site, which is found within the N-terminal
extension unique to PDE3A1, stimulates cAMP-hydrolytic activity,
providing another mechanism by which PDE3A1 can be selectively
regulated (31).
[0275] Our results showing that the interaction of PDE3A1 with
SERCA2a is dependent upon the phosphorylation of S292/S293 reveals
a new and important mechanism through which its unique N-terminal
extension regulates PDE3A1 function. The amino-acid sequence
surrounding this site, aa 288-294, is RRRRSSS, and all three
serines can be phosphorylated in vitro under different conditions
(31); hence it is likely this site can be phosphorylated by
different kinases activated in response to different upstream
signals. Phosphorylation at S292/S293 may promote direct
interactions of PDE3A1-binding proteins such as SERCA2a with this
site. Alternatively, phosphorylation at S292/S293 may influence the
conformation of PDE3A1 allosterically to promote binding to a
different protein-protein interface. In either case, our results
open the possibility that an agent capable of binding to PDE3A1 in
its 5292/5293-phosphorylated conformation may be able to inhibit
its phosphorylation-dependent protein-protein interactions, thereby
selectively inhibiting the integration of PDE3A1 into specific
complexes.
[0276] Our findings add to the understanding of the mechanisms
whereby PDE3A, a component of a SERCA2-containing signalosome,
regulates cAMP-mediated changes in contractility in cardiac
myocytes. Phosphorylation of PLB on amino acid S16 causes its
dissociation from SERCA2, relieving its inhibition of SERCA2
activity and increasing Ca.sup.2+ transport into the SR
(24,32,33).
[0277] These actions increase the amplitude of intracellular
Ca.sup.2+ transients, which are attenuated in dilated
cardiomyopathy (34). PKA-catalyzed phosphorylation of PLB at S16,
induced by isoproterenol, forskolin or IBMX, correlated with
increased cardiac relaxation (24,35). The interaction of PLB with
AKAP18 is also reduced by phosphorylation of S16 (2).
Phosphorylation of PDE3A1 at S292/S293, which leads to its
recruitment into the SERCA2 regulatory signalosome and to an
increase in its cAMP-hydrolytic activity, would tend to counteract
this effect by reducing the concentration of cAMP in the proximity
of this complex (FIG. 13). This combination of stimulation and
inhibition of SERCA2 activity in response to PKA activation through
separate mechanisms may permit a greater degree of `fine tuning` of
SR Ca.sup.2+ handling in response to .beta.-AR agonists. It may
also explain the synergism observed when PDE3 inhibitors are used
in combination with .beta.-AR agonists as inotropic agents. Since
PP2A and PP1 are thought to be the principal phosphatases
responsible for dephosphorylation of PKA substrates and PLB (36),
the presence of PP1 and PP2A in the complex would be expected to
catalyze the dephosphorylation of PDE3A, PLB and other PKA
substrates and return the SERCA2 complex to its basal state. Of
note, AKAP18 associates with inhibitor I and thereby can control
PP1 activity (37).
[0278] Our results have therapeutic implications. Selective
inhibition of the PDE3A isoforms associated with SERCA2 might allow
the inotropic benefits of stimulating Ca.sup.2+ transport into the
sarcoplasmic reticulum without the harmful effects of global
inhibition of PDE3 activity (38). Currently available PDE3
inhibitors, however, have little selectivity for PDE3A versus PDE3B
isoforms, whose catalytic domains are similar, and no selectivity
for individual PDE3A isoforms, whose catalytic domains are
identical (39). Blocking the integration of PDE3A1 into
SERCA2-containing complexes, either by blocking its phosphorylation
or by blocking the interactions of phosphorylated PDE3A1 with
SERCA2 and/or other constituents of the complexes, may be a way of
targeting PDE3 activity in a specific microdomain in cardiac
myocytes to stimulate SR Ca.sup.2+ uptake and produce inotropic
actions without the adverse consequences that accompany diffuse
increases in intracellular cAMP content.
REFERENCES:
[0279] 1. Sun, B., Li, H., Shakur, Y., Hensley, J., Hockman, S.,
Kambayashi, J., Manganiello, V. C., and Liu, Y. (2007)--Cell
Signal. 19, 1765-1771 [0280] 2. Lygren, B., Carlson, C. R.,
Santamaria, K., Lissandron, V., McSorley, T., Litzenberg, J.,
Lorenz, D., Wiesner, B., Rosenthal, W., Zaccolo, M., Tasken, K.,
and Klussmann, E. (2007)--Embo Rep. 8, 1061-1067 [0281] 3. Henn,
V., Edemir, B., Stefan, E., Wiesner, B., Lorenz, D., Theilig, F.,
Schmitt, R., Vossebein, L., Tamma, G., Beyermann, M., Krause, E.,
Herberg, F. W., Valenti, G., Bachmann, S., Rosenthal, W., and
Klussmann, E. (2004) J Biol. Chem. 279, 26654-26665 [0282] 4.
Ahmad, F., Lindh, R., Tang, Y., Weston, M., Degerman, E., and
Manganiello, V. C. (2007)--Biochem 1 404, 257-268 [0283] 5. Ahmad,
F., Lindh, R., Tang, Y., Ruishalme, I., Ost, A., Sahachartsiri, B.,
Stralfors, P., Degerman, E., and Manganiello, V. C. (2009)--Biochem
1 424, 399-410 [0284] 6. Onuma, H., Osawa, H., Yamada, K., Ogura,
T., Tanabe, F., Granner, D. K., and Makino, H. (2002)--Diabetes.
51, 3362-3367 [0285] 7. Palmer, D., Jimmo, S. L., Raymond, D. R.,
Wilson, L. S., Carter, R. L., and Maurice, D. H. (2007)--J Biol
Chem. 282, 9411-9419 [0286] 8. Nilsson, R., Ahmad, F., Sward, K.,
Andersson, U., Weston, M., Manganiello, V., and Degerman, E.
(2006)--Cell Signal. 18, 1713-1721 [0287] 9. Rondinone, C. M.,
Carvalho, E., Rahn, T., Manganiello, V. C., Degerman, E., and
Smith, U. P. (2000)--J Biol Chem. 275, 10093-10098 [0288] 10.
Perino, A., Ghigo, A., Ferrero, E., Morello, F., Santulli, G.,
Baillie, G. S., Damilano, F., Dunlop, A. J., Pawson, C., Walser,
R., Levi, R., Altruda, F., Silengo, L., Langeberg, L. K., Neubauer,
G., Heymans, S., Lembo, G., Wymann, M. P., Wetzker, R., Houslay, M.
D., Iaccarino, G., Scott, J. D., and Hirsch, E. (2011)--Mol Cell.
42, 84-95 [0289] 11. Wilson, L. S., Baillie, G. S., Pritchard, L.
M., Umana, B., Terrin, A., Zaccolo, M., Houslay, M. D., and
Maurice, D. H. (2011)--J Biol Chem. 286, 16285-96 [0290] 12.
Pozuelo, R. M., Campbell, D. G., Morrice, N. A., and Mackintosh, C.
(2005)--Biochem 1 392, 163-172 [0291] 13. Hunter, R. W.,
Mackintosh, C., and Hers, I. (2009) J Biol Chem. 284(18),
12339-12348 [0292] 14. Vandeput, F., Szabo-Fresnais, N., Ahmad, F.,
Kho, C., Lee, A., Krall, J., Dunlop, A., Hazel, M. W.,
Wohlschlegel, J. A., Hajjar, R. J., Houslay, M. D., Manganiello, V.
C., and Movsesian, M. A. (2013) Proc Natl Acad Sci USA. 110(49),
19778-19783 [0293] 15. Babick, A. P., Cantor, E. J., Babick, J. T.,
Takeda, N., Dhalla, N. S., and Netticadan, T. (2004)--Am J Physiol
Cell Physiol. 287, C1202-C1208 [0294] 16. Manganiello, V. and
Vaughan, M. (1973)--J Biol Chem. 248, 7164-7170 [0295] 17. Mishra,
S., Sabbah, H. N., Rastogi, S., Imai, M., and Gupta, R. C.
(2005)--Heart Vessels. 20, 23-32 [0296] 18. Kirchgesser, M. and
Dahlmann, N. (1990)--J Clin Chem Clin Biochem. 28, 407-411 [0297]
19. Wechsler, J., Choi, Y. H., Krall, J., Ahmad, F., Manganiello,
V. C., and Movsesian, M. A. (2002)--J Biol Chem. 277, 38072-38078
[0298] 20. Shakur, Y., Takeda, K., Kenan, Y., Yu, Z. X., Rena, G.,
Brandt, D., Houslay, M. D., Degerman, E., Ferrans, V. J., and
Manganiello, V. C. (2000) J Biol Chem. 275(49), 38749-38761 [0299]
21. Vandeput, F., Wolda, S. L., Krall, J., Hambleton, R., Uher, L.,
McCaw, K. N., Radwanski, P. B., Florio, V., and Movsesian, M. A.
(2007)--J Biol Chem. 282, 32749-32757 [0300] 22. Beca, S., Ahmad,
F., Shen, W., Liu, J., Makary, S., Polidovitch, N., Sun, J.,
Hockman, S., Chung, Y. W., Movsesian, M., Murphy, E., Manganiello,
V., and Backx, P. H. (2013) Circ. Res. 112(2), 289-297 [0301] 23.
Richter, W., Xie, M., Scheitrum, C., Krall, J., Movsesian, M., and
Conti M (2011)--Basic Res Cardiol. 106, 249-262 [0302] 24.
MacLennan, D. H. and Kranias, E. G. (2003)--Nat Rev Mol Cell Biol.
4, 566-577 [0303] 25. Yan, C., Miller, C. L., and Abe, J.
(2007)--Circ Res. 100, 489-501 [0304] 26. Mongillo, M., McSorley,
T., Evellin, S., Sood, A., Lissandron, V., Terrin, A., Huston, E.,
Hannawacker, A., Lohse, M. J., Pozzan, T., Houslay, M. D., and
Zaccolo, M. (2004)--Circ Res. 95, 67-75 [0305] 27. Houslay, M. D.,
Baillie, G. S., and Maurice, D. H. (2007)--Circ Res. 100, 950-966
[0306] 28. Zaccolo, M. (2009)--Br J Pharmacol. 158, 50-60 [0307]
29. Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J., and
Manganiello, V. C. (2014) Nat Rev Drug Discov. 13(4), 290-314
[0308] 30. Weninger, S., Van, C. K., Cameron, R. T., Vandeput, F.,
Movsesian, M. A., Baillie, G. S., and Lefebvre, R. A. (2014) Cell
Signal. 26(11), 2573-2582 [0309] 31. Han, S. J., Vaccari, S.,
Nedachi, T., Andersen, C. B., Kovacina, K. S., Roth, R. A., and
Conti, M. (2006) EMBO J, 25(24), 5716-5725 [0310] 32. Simmerman, H.
K. and Jones, L. R. (1998)--Physiol Rev. 78, 921-947 [0311] 33.
Sande, J. B., Sjaastad, I., Hoen, I. B., Bokenes, J., Tonnessen,
T., Holt, E., Lunde, P. K., and Christensen, G. (2002)--Cardiovasc
Res. 53, 382-391 [0312] 34. Kawase, Y. and Hajjar, R. J.
(2008)--Nat Clin Pract Cardiovasc Med. 5, 554-565 [0313] 35.
Kuschel, M., Karczewski, P., Hempel, P., Schlegel, W. P., Krause,
E. G., and Bartel, S. (1999)--Am J Physiol. 276 (5 Pt 2), H1625-33
[0314] 36. Schwoerer, A. P., Neuber, C., Schmechel, A.,
Melnychenko, I., Mearini, G., Boknik, P., Kirchhefer, U., Schmitz,
W., Ehmke, H., Eschenhagen, T., and El-Armouche, A. (2008)--J Mol
Cell Cardiol. 45, 846-852 [0315] 37. Singh, A., Redden, J. M.,
Kapiloff, M. S., and Dodge-Kafka, K. L. (2011) Mol Pharmacol.
79(3), 533-540 [0316] 38. Movsesian, M. A. (2003)--J Card Fail. 9,
475-480 [0317] 39. Hambleton, R., Krall, J., Tikishvili, E.,
Honeggar, M., Ahmad, F., Manganiello, V. C., and Movsesian, M. A.
(2005)--J Biol Chem. 280, 39168-39174
Sequence CWU 1
1
211141PRTHomo sapiensMISC_FEATURE(1)..(1141)conceptual translation
of the longest open reading frame (ORF) of the PDE3A
geneMISC_FEATURE(146)..(1141)PDE3A1 isoform
sequenceMISC_FEATURE(300)..(1141)PDE3A2 isoform
sequenceMISC_FEATURE(484)..(1141)PDE3A3 isoform sequence 1Met Ala
Val Pro Gly Asp Ala Ala Arg Val Arg Asp Lys Pro Val His 1 5 10 15
Ser Gly Val Ser Gln Ala Pro Thr Ala Gly Arg Asp Cys His His Arg 20
25 30 Ala Asp Pro Ala Ser Pro Arg Asp Ser Gly Cys Arg Gly Cys Trp
Gly 35 40 45 Asp Leu Val Leu Gln Pro Leu Arg Ser Ser Arg Lys Leu
Ser Ser Ala 50 55 60 Leu Cys Ala Gly Ser Leu Ser Phe Leu Leu Ala
Leu Leu Val Arg Leu 65 70 75 80 Val Arg Gly Glu Val Gly Cys Asp Leu
Glu Gln Cys Lys Glu Ala Ala 85 90 95 Ala Ala Glu Glu Glu Glu Ala
Ala Pro Gly Ala Glu Gly Gly Val Phe 100 105 110 Pro Gly Pro Arg Gly
Gly Ala Pro Gly Gly Gly Ala Arg Leu Ser Pro 115 120 125 Trp Leu Gln
Pro Ser Ala Leu Leu Phe Ser Leu Leu Cys Ala Phe Phe 130 135 140 Trp
Met Gly Leu Tyr Leu Leu Arg Ala Gly Val Arg Leu Pro Leu Ala 145 150
155 160 Val Ala Leu Leu Ala Ala Cys Cys Gly Gly Glu Ala Leu Val Gln
Ile 165 170 175 Gly Leu Gly Val Gly Glu Asp His Leu Leu Ser Leu Pro
Ala Ala Gly 180 185 190 Val Val Leu Ser Cys Leu Ala Ala Ala Thr Trp
Leu Val Leu Arg Leu 195 200 205 Arg Leu Gly Val Leu Met Ile Ala Leu
Thr Ser Ala Val Arg Thr Val 210 215 220 Ser Leu Ile Ser Leu Glu Arg
Phe Lys Val Ala Trp Arg Pro Tyr Leu 225 230 235 240 Ala Tyr Leu Ala
Gly Val Leu Gly Ile Leu Leu Ala Arg Tyr Val Glu 245 250 255 Gln Ile
Leu Pro Gln Ser Ala Glu Ala Ala Pro Arg Glu His Leu Gly 260 265 270
Ser Gln Leu Ile Ala Gly Thr Lys Glu Asp Ile Pro Val Phe Lys Arg 275
280 285 Arg Arg Arg Ser Ser Ser Val Val Ser Ala Glu Met Ser Gly Cys
Ser 290 295 300 Ser Lys Ser His Arg Arg Thr Ser Leu Pro Cys Ile Pro
Arg Glu Gln 305 310 315 320 Leu Met Gly His Ser Glu Trp Asp His Lys
Arg Gly Pro Arg Gly Ser 325 330 335 Gln Ser Ser Gly Thr Ser Ile Thr
Val Asp Ile Ala Val Met Gly Glu 340 345 350 Ala His Gly Leu Ile Thr
Asp Leu Leu Ala Asp Pro Ser Leu Pro Pro 355 360 365 Asn Val Cys Thr
Ser Leu Arg Ala Val Ser Asn Leu Leu Ser Thr Gln 370 375 380 Leu Thr
Phe Gln Ala Ile His Lys Pro Arg Val Asn Pro Val Thr Ser 385 390 395
400 Leu Ser Glu Asn Tyr Thr Cys Ser Asp Ser Glu Glu Ser Ser Glu Lys
405 410 415 Asp Lys Leu Ala Ile Pro Lys Arg Leu Arg Arg Ser Leu Pro
Pro Gly 420 425 430 Leu Leu Arg Arg Val Ser Ser Thr Trp Thr Thr Thr
Thr Ser Ala Thr 435 440 445 Gly Leu Pro Thr Leu Glu Pro Ala Pro Val
Arg Arg Asp Arg Ser Thr 450 455 460 Ser Ile Lys Leu Gln Glu Ala Pro
Ser Ser Ser Pro Asp Ser Trp Asn 465 470 475 480 Asn Pro Val Met Met
Thr Leu Thr Lys Ser Arg Ser Phe Thr Ser Ser 485 490 495 Tyr Ala Ile
Ser Ala Ala Asn His Val Lys Ala Lys Lys Gln Ser Arg 500 505 510 Pro
Gly Ala Leu Ala Lys Ile Ser Pro Leu Ser Ser Pro Cys Ser Ser 515 520
525 Pro Leu Gln Gly Thr Pro Ala Ser Ser Leu Val Ser Lys Ile Ser Ala
530 535 540 Val Gln Phe Pro Glu Ser Ala Asp Thr Thr Ala Lys Gln Ser
Leu Gly 545 550 555 560 Ser His Arg Ala Leu Thr Tyr Thr Gln Ser Ala
Pro Asp Leu Ser Pro 565 570 575 Gln Ile Leu Thr Pro Pro Val Ile Cys
Ser Ser Cys Gly Arg Pro Tyr 580 585 590 Ser Gln Gly Asn Pro Ala Asp
Glu Pro Leu Glu Arg Ser Gly Val Ala 595 600 605 Thr Arg Thr Pro Ser
Arg Thr Asp Asp Thr Ala Gln Val Thr Ser Asp 610 615 620 Tyr Glu Thr
Asn Asn Asn Ser Asp Ser Ser Asp Ile Val Gln Asn Glu 625 630 635 640
Asp Glu Thr Glu Cys Leu Arg Glu Pro Leu Arg Lys Ala Ser Ala Cys 645
650 655 Ser Thr Tyr Ala Pro Glu Thr Met Met Phe Leu Asp Lys Pro Ile
Leu 660 665 670 Ala Pro Glu Pro Leu Val Met Asp Asn Leu Asp Ser Ile
Met Glu Gln 675 680 685 Leu Asn Thr Trp Asn Phe Pro Ile Phe Asp Leu
Val Glu Asn Ile Gly 690 695 700 Arg Lys Cys Gly Arg Ile Leu Ser Gln
Val Ser Tyr Arg Leu Phe Glu 705 710 715 720 Asp Met Gly Leu Phe Glu
Ala Phe Lys Ile Pro Ile Arg Glu Phe Met 725 730 735 Asn Tyr Phe His
Ala Leu Glu Ile Gly Tyr Arg Asp Ile Pro Tyr His 740 745 750 Asn Arg
Ile His Ala Thr Asp Val Leu His Ala Val Trp Tyr Leu Thr 755 760 765
Thr Gln Pro Ile Pro Gly Leu Ser Thr Val Ile Asn Asp His Gly Ser 770
775 780 Thr Ser Asp Ser Asp Ser Asp Ser Gly Phe Thr His Gly His Met
Gly 785 790 795 800 Tyr Val Phe Ser Lys Thr Tyr Asn Val Thr Asp Asp
Lys Tyr Gly Cys 805 810 815 Leu Ser Gly Asn Ile Pro Ala Leu Glu Leu
Met Ala Leu Tyr Val Ala 820 825 830 Ala Ala Met His Asp Tyr Asp His
Pro Gly Arg Thr Asn Ala Phe Leu 835 840 845 Val Ala Thr Ser Ala Pro
Gln Ala Val Leu Tyr Asn Asp Arg Ser Val 850 855 860 Leu Glu Asn His
His Ala Ala Ala Ala Trp Asn Leu Phe Met Ser Arg 865 870 875 880 Pro
Glu Tyr Asn Phe Leu Ile Asn Leu Asp His Val Glu Phe Lys His 885 890
895 Phe Arg Phe Leu Val Ile Glu Ala Ile Leu Ala Thr Asp Leu Lys Lys
900 905 910 His Phe Asp Phe Val Ala Lys Phe Asn Gly Lys Val Asn Asp
Asp Val 915 920 925 Gly Ile Asp Trp Thr Asn Glu Asn Asp Arg Leu Leu
Val Cys Gln Met 930 935 940 Cys Ile Lys Leu Ala Asp Ile Asn Gly Pro
Ala Lys Cys Lys Glu Leu 945 950 955 960 His Leu Gln Trp Thr Asp Gly
Ile Val Asn Glu Phe Tyr Glu Gln Gly 965 970 975 Asp Glu Glu Ala Ser
Leu Gly Leu Pro Ile Ser Pro Phe Met Asp Arg 980 985 990 Ser Ala Pro
Gln Leu Ala Asn Leu Gln Glu Ser Phe Ile Ser His Ile 995 1000 1005
Val Gly Pro Leu Cys Asn Ser Tyr Asp Ser Ala Gly Leu Met Pro 1010
1015 1020 Gly Lys Trp Val Glu Asp Ser Asp Glu Ser Gly Asp Thr Asp
Asp 1025 1030 1035 Pro Glu Glu Glu Glu Glu Glu Ala Pro Ala Pro Asn
Glu Glu Glu 1040 1045 1050 Thr Cys Glu Asn Asn Glu Ser Pro Lys Lys
Lys Thr Phe Lys Arg 1055 1060 1065 Arg Lys Ile Tyr Cys Gln Ile Thr
Gln His Leu Leu Gln Asn His 1070 1075 1080 Lys Met Trp Lys Lys Val
Ile Glu Glu Glu Gln Arg Leu Ala Gly 1085 1090 1095 Ile Glu Asn Gln
Ser Leu Asp Gln Thr Pro Gln Ser His Ser Ser 1100 1105 1110 Glu Gln
Ile Gln Ala Ile Lys Glu Glu Glu Glu Glu Lys Gly Lys 1115 1120 1125
Pro Arg Gly Glu Glu Ile Pro Thr Gln Lys Pro Asp Gln 1130 1135 1140
21141PRTHomo sapiensMISC_FEATURE(1)..(1141)conceptual translation
of the longest ORF of the PDE3A gene with a mutation at amino acid
position 1004 in which phenylalanine is changed to alanine;
presence of alanine at amino acid 1004 inactivates
phosphodiesterase activity 2Met Ala Val Pro Gly Asp Ala Ala Arg Val
Arg Asp Lys Pro Val His 1 5 10 15 Ser Gly Val Ser Gln Ala Pro Thr
Ala Gly Arg Asp Cys His His Arg 20 25 30 Ala Asp Pro Ala Ser Pro
Arg Asp Ser Gly Cys Arg Gly Cys Trp Gly 35 40 45 Asp Leu Val Leu
Gln Pro Leu Arg Ser Ser Arg Lys Leu Ser Ser Ala 50 55 60 Leu Cys
Ala Gly Ser Leu Ser Phe Leu Leu Ala Leu Leu Val Arg Leu 65 70 75 80
Val Arg Gly Glu Val Gly Cys Asp Leu Glu Gln Cys Lys Glu Ala Ala 85
90 95 Ala Ala Glu Glu Glu Glu Ala Ala Pro Gly Ala Glu Gly Gly Val
Phe 100 105 110 Pro Gly Pro Arg Gly Gly Ala Pro Gly Gly Gly Ala Arg
Leu Ser Pro 115 120 125 Trp Leu Gln Pro Ser Ala Leu Leu Phe Ser Leu
Leu Cys Ala Phe Phe 130 135 140 Trp Met Gly Leu Tyr Leu Leu Arg Ala
Gly Val Arg Leu Pro Leu Ala 145 150 155 160 Val Ala Leu Leu Ala Ala
Cys Cys Gly Gly Glu Ala Leu Val Gln Ile 165 170 175 Gly Leu Gly Val
Gly Glu Asp His Leu Leu Ser Leu Pro Ala Ala Gly 180 185 190 Val Val
Leu Ser Cys Leu Ala Ala Ala Thr Trp Leu Val Leu Arg Leu 195 200 205
Arg Leu Gly Val Leu Met Ile Ala Leu Thr Ser Ala Val Arg Thr Val 210
215 220 Ser Leu Ile Ser Leu Glu Arg Phe Lys Val Ala Trp Arg Pro Tyr
Leu 225 230 235 240 Ala Tyr Leu Ala Gly Val Leu Gly Ile Leu Leu Ala
Arg Tyr Val Glu 245 250 255 Gln Ile Leu Pro Gln Ser Ala Glu Ala Ala
Pro Arg Glu His Leu Gly 260 265 270 Ser Gln Leu Ile Ala Gly Thr Lys
Glu Asp Ile Pro Val Phe Lys Arg 275 280 285 Arg Arg Arg Ser Ser Ser
Val Val Ser Ala Glu Met Ser Gly Cys Ser 290 295 300 Ser Lys Ser His
Arg Arg Thr Ser Leu Pro Cys Ile Pro Arg Glu Gln 305 310 315 320 Leu
Met Gly His Ser Glu Trp Asp His Lys Arg Gly Pro Arg Gly Ser 325 330
335 Gln Ser Ser Gly Thr Ser Ile Thr Val Asp Ile Ala Val Met Gly Glu
340 345 350 Ala His Gly Leu Ile Thr Asp Leu Leu Ala Asp Pro Ser Leu
Pro Pro 355 360 365 Asn Val Cys Thr Ser Leu Arg Ala Val Ser Asn Leu
Leu Ser Thr Gln 370 375 380 Leu Thr Phe Gln Ala Ile His Lys Pro Arg
Val Asn Pro Val Thr Ser 385 390 395 400 Leu Ser Glu Asn Tyr Thr Cys
Ser Asp Ser Glu Glu Ser Ser Glu Lys 405 410 415 Asp Lys Leu Ala Ile
Pro Lys Arg Leu Arg Arg Ser Leu Pro Pro Gly 420 425 430 Leu Leu Arg
Arg Val Ser Ser Thr Trp Thr Thr Thr Thr Ser Ala Thr 435 440 445 Gly
Leu Pro Thr Leu Glu Pro Ala Pro Val Arg Arg Asp Arg Ser Thr 450 455
460 Ser Ile Lys Leu Gln Glu Ala Pro Ser Ser Ser Pro Asp Ser Trp Asn
465 470 475 480 Asn Pro Val Met Met Thr Leu Thr Lys Ser Arg Ser Phe
Thr Ser Ser 485 490 495 Tyr Ala Ile Ser Ala Ala Asn His Val Lys Ala
Lys Lys Gln Ser Arg 500 505 510 Pro Gly Ala Leu Ala Lys Ile Ser Pro
Leu Ser Ser Pro Cys Ser Ser 515 520 525 Pro Leu Gln Gly Thr Pro Ala
Ser Ser Leu Val Ser Lys Ile Ser Ala 530 535 540 Val Gln Phe Pro Glu
Ser Ala Asp Thr Thr Ala Lys Gln Ser Leu Gly 545 550 555 560 Ser His
Arg Ala Leu Thr Tyr Thr Gln Ser Ala Pro Asp Leu Ser Pro 565 570 575
Gln Ile Leu Thr Pro Pro Val Ile Cys Ser Ser Cys Gly Arg Pro Tyr 580
585 590 Ser Gln Gly Asn Pro Ala Asp Glu Pro Leu Glu Arg Ser Gly Val
Ala 595 600 605 Thr Arg Thr Pro Ser Arg Thr Asp Asp Thr Ala Gln Val
Thr Ser Asp 610 615 620 Tyr Glu Thr Asn Asn Asn Ser Asp Ser Ser Asp
Ile Val Gln Asn Glu 625 630 635 640 Asp Glu Thr Glu Cys Leu Arg Glu
Pro Leu Arg Lys Ala Ser Ala Cys 645 650 655 Ser Thr Tyr Ala Pro Glu
Thr Met Met Phe Leu Asp Lys Pro Ile Leu 660 665 670 Ala Pro Glu Pro
Leu Val Met Asp Asn Leu Asp Ser Ile Met Glu Gln 675 680 685 Leu Asn
Thr Trp Asn Phe Pro Ile Phe Asp Leu Val Glu Asn Ile Gly 690 695 700
Arg Lys Cys Gly Arg Ile Leu Ser Gln Val Ser Tyr Arg Leu Phe Glu 705
710 715 720 Asp Met Gly Leu Phe Glu Ala Phe Lys Ile Pro Ile Arg Glu
Phe Met 725 730 735 Asn Tyr Phe His Ala Leu Glu Ile Gly Tyr Arg Asp
Ile Pro Tyr His 740 745 750 Asn Arg Ile His Ala Thr Asp Val Leu His
Ala Val Trp Tyr Leu Thr 755 760 765 Thr Gln Pro Ile Pro Gly Leu Ser
Thr Val Ile Asn Asp His Gly Ser 770 775 780 Thr Ser Asp Ser Asp Ser
Asp Ser Gly Phe Thr His Gly His Met Gly 785 790 795 800 Tyr Val Phe
Ser Lys Thr Tyr Asn Val Thr Asp Asp Lys Tyr Gly Cys 805 810 815 Leu
Ser Gly Asn Ile Pro Ala Leu Glu Leu Met Ala Leu Tyr Val Ala 820 825
830 Ala Ala Met His Asp Tyr Asp His Pro Gly Arg Thr Asn Ala Phe Leu
835 840 845 Val Ala Thr Ser Ala Pro Gln Ala Val Leu Tyr Asn Asp Arg
Ser Val 850 855 860 Leu Glu Asn His His Ala Ala Ala Ala Trp Asn Leu
Phe Met Ser Arg 865 870 875 880 Pro Glu Tyr Asn Phe Leu Ile Asn Leu
Asp His Val Glu Phe Lys His 885 890 895 Phe Arg Phe Leu Val Ile Glu
Ala Ile Leu Ala Thr Asp Leu Lys Lys 900 905 910 His Phe Asp Phe Val
Ala Lys Phe Asn Gly Lys Val Asn Asp Asp Val 915 920 925 Gly Ile Asp
Trp Thr Asn Glu Asn Asp Arg Leu Leu Val Cys Gln Met 930 935 940 Cys
Ile Lys Leu Ala Asp Ile Asn Gly Pro Ala Lys Cys Lys Glu Leu 945 950
955 960 His Leu Gln Trp Thr Asp Gly Ile Val Asn Glu Phe Tyr Glu Gln
Gly 965 970 975 Asp Glu Glu Ala Ser Leu Gly Leu Pro Ile Ser Pro Phe
Met Asp Arg 980 985 990 Ser Ala Pro Gln Leu Ala Asn Leu Gln Glu Ser
Ala Ile Ser His Ile 995 1000 1005 Val Gly Pro Leu Cys Asn Ser Tyr
Asp Ser Ala Gly Leu Met Pro 1010 1015 1020 Gly Lys Trp Val Glu Asp
Ser Asp Glu Ser Gly Asp Thr Asp Asp 1025 1030 1035 Pro Glu Glu Glu
Glu Glu Glu Ala Pro Ala Pro Asn Glu Glu Glu 1040 1045 1050 Thr Cys
Glu Asn Asn Glu Ser Pro Lys Lys Lys Thr Phe Lys Arg 1055 1060 1065
Arg Lys Ile Tyr Cys Gln Ile Thr Gln His Leu Leu
Gln Asn His 1070 1075 1080 Lys Met Trp Lys Lys Val Ile Glu Glu Glu
Gln Arg Leu Ala Gly 1085 1090 1095 Ile Glu Asn Gln Ser Leu Asp Gln
Thr Pro Gln Ser His Ser Ser 1100 1105 1110 Glu Gln Ile Gln Ala Ile
Lys Glu Glu Glu Glu Glu Lys Gly Lys 1115 1120 1125 Pro Arg Gly Glu
Glu Ile Pro Thr Gln Lys Pro Asp Gln 1130 1135 1140
* * * * *
References